<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc-domain-id">328</journal-id><journal-id journal-id-type="pmc-domain">ploscomp</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9671373</article-id><article-id pub-id-type="pmcid-ver">PMC9671373.1</article-id><article-id pub-id-type="pmcaid">9671373</article-id><article-id pub-id-type="pmcaiid">9671373</article-id><article-id pub-id-type="pmid">36395103</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1010685</article-id><article-id pub-id-type="publisher-id">PCOMPBIOL-D-22-00152</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Malignant Tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Simulation and Modeling</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Head and Neck Cancers</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Breast Tumors</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA repair</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA repair</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive System</subject><subj-group><subject>Gastrointestinal Tract</subject><subj-group><subject>Colon</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive System</subject><subj-group><subject>Gastrointestinal Tract</subject><subj-group><subject>Colon</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model</article-title><alt-title alt-title-type="running-head">Computational analysis of 5-fluorouracil anti-tumor activity</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7366-7602</contrib-id><name name-style="western"><surname>Ma</surname><given-names initials="C">Chenhui</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almasan</surname><given-names initials="A">Alex</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9626-0848</contrib-id><name name-style="western"><surname>Gurkan-Cavusoglu</surname><given-names initials="E">Evren</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Electrical, Computer and Systems Engineering, Case Western Reserve University, Cleveland, Ohio, United States of America</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Gallo</surname><given-names initials="J">James</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>University at Buffalo - The State University of New York, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>chenhui.ma@case.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2022</year></pub-date><volume>18</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">420684</issue-id><elocation-id>e1010685</elocation-id><history><date date-type="received"><day>31</day><month>1</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>11</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>18</day><month>11</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-11-19 02:10:11.980"><day>19</day><month>11</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 Ma et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Ma et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pcbi.1010685.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pcbi.1010685.pdf"/><abstract><p>5-Fluorouracil (5-FU) is a standard chemotherapeutic agent to treat solid cancers such as breast, colon, head, and neck. Computational modeling plays an essential role in predicting the outcome of chemotherapy and developing optimal dosing strategies. We developed an integrated mechanistic pharmacokinetics/pharmacodynamics (PK/PD) model examining the influence of 5-FU, as an S-phase specific double-strand break (DSB)-inducing agent, on tumor proliferation. The proposed mechanistic PK/PD model simulates the dynamics of critical intermediate components and provides the accurate tumor response prediction. The integrated model is composed of PK, cellular, and tumor growth inhibition (TGI) sub-models, quantitatively capturing the essential drug-related physiological processes. In the cellular model, thymidylate synthase (TS) inhibition, resultant deoxynucleoside triphosphate (dNTP) pool imbalance, and DSB induction are considered, as well as 5-FU incorporation into RNA and DNA. The amount of 5-FU anabolites and DSBs were modeled to drive the kinetics of the pharmacological tumor response. Model parameters were estimated by fitting to literature data. Our simulation results successfully describe the kinetics of the intermediates regulating the 5-FU cytotoxic events and the pattern of tumor suppression. The comprehensive model simulated the tumor volume change under various dose regimens, and its generalizability was attested by comparing it with literature data. The potential causes of the tumor resistance to 5-FU are also investigated through Monte Carlo analysis. The simulation of various dosage regimens helps quantify the relationship between treatment protocols and chemotherapy potency, which will lead to the development of efficacy optimization.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Computational modeling plays an essential role in predicting the outcome of chemotherapy and developing optimal dosing strategies. In this study, we developed a computational model examining the influence of a chemotherapeutic agent, 5-fluorouracil, on tumor proliferation. 5-fluorouracil is a standard chemotherapeutic agent used to treat solid cancers such as breast, colon, head, and neck. Our model traces the dynamics of critical intermediate components and generates the accurate tumor response prediction in a physiologically-based manner for colon cancer. The comprehensive model simulates the tumor volume change under various dosage regimens, and its generalizability is attested by the validation against literature data. We used the models to investigate potential causes of the tumor resistance to 5-fluorouracil. Our model simulations for various dosage regimens help quantify the relationship between treatment protocols and chemotherapy potency.</p></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="7"/><page-count count="34"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data sources are specified within the manuscript. The code used to generate the results is available at the following public GitHub repository: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Chenhui88569/Computational-analysis-of-5-fluorouracil-anti-tumor-activity.git" ext-link-type="uri">https://github.com/Chenhui88569/Computational-analysis-of-5-fluorouracil-anti-tumor-activity.git</ext-link> and under the Zenodo archive: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.7267874" ext-link-type="uri">https://doi.org/10.5281/zenodo.7267874</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data sources are specified within the manuscript. The code used to generate the results is available at the following public GitHub repository: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Chenhui88569/Computational-analysis-of-5-fluorouracil-anti-tumor-activity.git" ext-link-type="uri">https://github.com/Chenhui88569/Computational-analysis-of-5-fluorouracil-anti-tumor-activity.git</ext-link> and under the Zenodo archive: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.7267874" ext-link-type="uri">https://doi.org/10.5281/zenodo.7267874</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>In this study, we developed a novel mechanistic PK/PD model that integrates a detailed cellular model with the classical PK/PD models to analyze the treatment outcome of the chemotherapeutic agent 5-fluorouracil (5-FU) in colon cancer. The modeling framework enables the quantitative analysis of the drug metabolism together with the downstream antiproliferative events by providing process models for the distribution of 5-FU from its entry into the body to interstitial fluid outside the tumor cells and to its cellular uptake. In the cell model, the connection of cellular level molecular events that lead to tumor suppression are modeled in detail. Over the past decades, pharmacokinetics/pharmacodynamics (PK/PD) models have been widely used in predicting therapeutic outcomes through the evaluation of the causal concentration-effect relationships [<xref rid="pcbi.1010685.ref001" ref-type="bibr">1</xref>]. Specifically, the PK model concentrates on drug disposition in plasma and/or tissues and describes drug exposure stages. In contrast, the PD model examines the pharmaceutical responses (e.g., tumor volume, white blood cell counts) following the drug treatment. The structures of the PK models differ based on the type of the drug, route of administration (i.e., oral absorption, intravenous injection, intravenous infusion), as well as the availability of clinical data. Commonly used compartment PK models in the literature are one compartment, two-compartment and three-compartment models. The one-compartment PK model considers the drug distribution in the whole organism as homogeneous [<xref rid="pcbi.1010685.ref002" ref-type="bibr">2</xref>]. The two-compartment PK model represents the transfer of substances between central (richly perfused organs) and peripheral regions (poorly perfused organs) of the human body [<xref rid="pcbi.1010685.ref003" ref-type="bibr">3</xref>, <xref rid="pcbi.1010685.ref004" ref-type="bibr">4</xref>]. One central and two peripheral compartments constitute three-compartment PK models [<xref rid="pcbi.1010685.ref005" ref-type="bibr">5</xref>, <xref rid="pcbi.1010685.ref006" ref-type="bibr">6</xref>]. The multicompartment pharmacokinetics models are preferred over the one-compartment model, because they can accurately represent the plasma concentration-time profile [<xref rid="pcbi.1010685.ref007" ref-type="bibr">7</xref>]. The pharmacokinetic profile in the central or peripheral compartment is the input of the PD model. The drug transport across the cell membrane is modeled as the irreversible or reversible exchange with the tumor compartment [<xref rid="pcbi.1010685.ref008" ref-type="bibr">8</xref>]. The PD model for tumor response comprises the kinetics of the control group and the treated group. The population tumor growth kinetics in the absence of the drug intervention is described by ordinary differential equations, including a growth term and a death term. Exponential, Mendelsohn, linear, logistic, Gompertz, and Bertalanffy are the common options for simulating the normal tumor growth patterns [<xref rid="pcbi.1010685.ref009" ref-type="bibr">9</xref>]. Specifically, exponential, Mendelsohn, linear, and surface growth terms predict that tumors will continue growing without an upper bound. Logistic, Gompertz, and Bertalanffy models predict that tumors will grow to some maximum size and reach a stable equilibrium at that point, based on the finding that the tumor growth is subject to the limited nutrition supply and extracellular cues [<xref rid="pcbi.1010685.ref009" ref-type="bibr">9</xref>, <xref rid="pcbi.1010685.ref010" ref-type="bibr">10</xref>]. Under the effect of tumor therapy, the tumor growth is altered and deviated from its baseline level. As a key player in PD model, the exposure-effect relationship(<italic toggle="yes">E</italic><sub><italic toggle="yes">drug</italic></sub>) driving the drug-induced tumor kinetics is modeled as a function of drug concentration, which can be linear, log-linear and sigmoid [<xref rid="pcbi.1010685.ref011" ref-type="bibr">11</xref>, <xref rid="pcbi.1010685.ref012" ref-type="bibr">12</xref>]. The involvement of drug effect in tumor growth dynamics can be modeled in various ways, depending on the biological question researchers propose to address, the assumptions on which the model construction is based, and the availability of experimental data. In general, the pharmacodynamic models take one or more of the forms of the hypothetical effect compartment model, indirect response model and signal transduction model, irreversible effect model, and complex mechanism-based model [<xref rid="pcbi.1010685.ref013" ref-type="bibr">13</xref>]. The interpretations of these PD models are provided as follows. The hypothetical effect compartment reproduces the true site of drug action and is applied between the PK and PD model only when the slow onset of observed effects can be explained by the rate-limiting drug distribution to the target site [<xref rid="pcbi.1010685.ref014" ref-type="bibr">14</xref>]. The indirect response model captures the nonlinear exposure-effect relationship and reflects how the reversible drug action alters the turnover of the drug response variables. Specifically, the sigmoid <italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub> can be added to the production and loss term to represent either inhibitory or stimulatory effects of drug disposition on the production or the loss of the responses [<xref rid="pcbi.1010685.ref015" ref-type="bibr">15</xref>, <xref rid="pcbi.1010685.ref016" ref-type="bibr">16</xref>]. The PD model encompassing the signaling pathways incorporates the time-dependent intermediate steps connecting the drug-receptor complex and pharmacodynamic response. The time elapsed from drug binding to the onset of the measurable responses is modeled by a transit compartment approach [<xref rid="pcbi.1010685.ref017" ref-type="bibr">17</xref>, <xref rid="pcbi.1010685.ref018" ref-type="bibr">18</xref>]. The irreversible effect model is similar to the indirect response model in certain contexts where the tumor growth is incorporated. But this type of PD model is only applicable to the compounds with irreversible anti-tumor effects and does not alter the turnover rate of a biomarker. The mechanism-based pharmacodynamic models extend from the indirect response model and consider the multiple drug-related mechanistic events represented by the ordinary or partial differential equations defined for the model variables [<xref rid="pcbi.1010685.ref019" ref-type="bibr">19</xref>]. The underlying physiological processes also warrant the additional modeling components to capture the biological phenomenon.</p><p>In recent years, researchers have shown great interest in employing PK/PD models for the prediction of tumor responses to 5-FU. Several conventional PK/PD models in the context of 5-FU treatment have been proposed, in which the transit compartment model is employed to describe the progressive effect on damaged tumor cells [<xref rid="pcbi.1010685.ref020" ref-type="bibr">20</xref>&#8211;<xref rid="pcbi.1010685.ref022" ref-type="bibr">22</xref>]. Although researchers have gained desirable analysis outcomes through the PK/PD models, the physiological effects under tumor treatment are barely captured. To delve into the complex cellular responses towards chemotherapy and to realize precise prediction, the mechanistic details need to be incorporated in the model design phase. In the literature, semi-mechanistic PK/PD models have been built for 5-FU in recent years, which employ both biological complexity and predictive power of a typical empirical model. In the model developed by Arshad et al. [<xref rid="pcbi.1010685.ref023" ref-type="bibr">23</xref>], three transit compartments describing blood cell maturation were used to explore the relationship between 5-FU exposure and myelosuppression. In a physiologically-based PK model [<xref rid="pcbi.1010685.ref024" ref-type="bibr">24</xref>], the activities of the metabolic enzymes regulating the metabolism of Capecitabine to 5-FU are considered to pursue a better prediction of the therapy efficacy. The study [<xref rid="pcbi.1010685.ref025" ref-type="bibr">25</xref>] aiming for characterizing the PK/PD relationship for LY2835219 developed an integrated model incorporating CDK4/6 inhibition, cell-cycle arrest, and tumor growth inhibition. Altinok et al. proposed a cellular automaton model coupled with a PK model to investigate the effects of circadian rhythms on the therapeutic outcome of 5-FU [<xref rid="pcbi.1010685.ref026" ref-type="bibr">26</xref>]. Recognizing the benefits brought about by this type of computational model, we developed a mechanistic PK/PD model which encompasses multi-level biological phenomenon to capture the drug actions of 5-FU in the tumor cells.</p><p>5-FU exhibits its cytotoxicity through a metabolic pathway that has been widely studied since its approval. 80%-90% of 5-FU is further decomposed into simple molecules through catabolism taking place in the liver by dihydro-pyrimidine dehydrogenase (DPD), while its active forms of metabolites are produced through anabolism in tumor cells [<xref rid="pcbi.1010685.ref027" ref-type="bibr">27</xref>]. It is 5-FU anabolites that intervene in the normal cellular functions and exhibit deleterious effects on tumor growth. Fluoro-deoxyuridinetriphosphate (FdUTP) and fluorouridine triphosphate(FUTP) are the products of sequential phosphorylations initially catalyzed by thymidine phosphorylase (dThdPase) and uridine phosphorylase (UrdPase) or orotate phosphoribosyl transferase (OPRT), respectively [<xref rid="pcbi.1010685.ref028" ref-type="bibr">28</xref>, <xref rid="pcbi.1010685.ref029" ref-type="bibr">29</xref>]. They are ultimately incorporated in RNA and DNA through the action of DNA polymerase, causing genomic instability. The conversion of 5-FU to fluorodeoxyuridine (FUDR) is followed by the production of fluorodeoxyuridylate (FdUMP) catalyzed by thymidine kinase (TK). FdUMP binds to thymidylate synthase (TS) at its nucleotide site in competition with deoxyuridine monophosphate (dUMP) and forms a ternary complex with a folate analog 5,10-methylenetetrahydrofolate (CH2THF) as a co-substrate, leading to reversible inactivation of TS enzymatic activity and inhibition of thymidine production [<xref rid="pcbi.1010685.ref030" ref-type="bibr">30</xref>, <xref rid="pcbi.1010685.ref031" ref-type="bibr">31</xref>].</p><p>Accumulating evidence indicates that TS inhibition is the determinant of 5-FU&#8217;s anti-tumor effects and its activity has been demonstrated to be the predictor of tumor response to 5-FU treatment [<xref rid="pcbi.1010685.ref031" ref-type="bibr">31</xref>&#8211;<xref rid="pcbi.1010685.ref033" ref-type="bibr">33</xref>]. Hence, in our model, the dNTP pool imbalance caused by TS inhibition is attributed to the key factor in the formation of deleterious DNA fragmentation. The intactness of the components in the dNTP pool is required for DNA replication and DNA repair machinery to perform with high fidelity [<xref rid="pcbi.1010685.ref034" ref-type="bibr">34</xref>]. The thymidine deprivation and resulting dUMP accumulation can give rise to the perturbation of the biosynthesis of the other deoxynucleotides (dATP, dGTP, dCTP) via multiple feedback mechanisms. Interruption of biosynthesis of DNA precursors caused by the deficiency of the enzymes involved in nucleotide metabolism can give rise to futile DNA damage repair and accumulated DSBs [<xref rid="pcbi.1010685.ref035" ref-type="bibr">35</xref>]. (F)dUTP insertions into DNA facilitated by dUMP accumulation are recognized and excised by uracil DNA glycosylase (UNG), the first responder of the BER pathway [<xref rid="pcbi.1010685.ref036" ref-type="bibr">36</xref>]. But the uracil bases are incorporated repeatedly, causing the futile cycling repair by BER [<xref rid="pcbi.1010685.ref036" ref-type="bibr">36</xref>]. The accumulation of BER intermediates such as AP sites and single-strand breaks (SSBs) and persistent breakages triggers the formation of DSBs, resulting in cell cycle arrest, activation of homologous recombination repair(HRR), and apoptosis pathways. Indeed, some studies have established the relationship between the dNTP pool imbalance and 5-FU cytotoxicity [<xref rid="pcbi.1010685.ref032" ref-type="bibr">32</xref>, <xref rid="pcbi.1010685.ref037" ref-type="bibr">37</xref>].</p><p>In this study, we constructed a detailed mechanistic model linking the concrete drug actions of 5-FU to the prediction of pharmacodynamic response of colon cancer cells. The cellular model focuses on 5-FU anabolism, RNA and DNA misincorporation, TS inhibition leading to contamination of the dNTP pool, and induction of DSBs when the cell population proceeds through the S phase, all of which are believed to be essential biological events upon the administration of 5-FU. In addition, we used the <italic toggle="yes">&#947;</italic>-H2AX foci count to approximate DSBs, <italic toggle="yes">&#947;</italic>-H2AX is the canonical biomarker of DSBs, and its qualitative consistency with DSBs has been well established in the literature [<xref rid="pcbi.1010685.ref038" ref-type="bibr">38</xref>]. The tumor growth inhibition (TGI) model is built based on the combination of the life span model and the indirect response model, and the dynamics of the normal tumor growth is captured by the logistic growth model involving carrying capacity. Considering the suppressive effect of drug on tumor growth, 5-FU anabolites are modeled to inhibit the tumor growth and 5-FU-induced DSB formation is modeled accelerate the conversion of proliferating cells to damaged cells, which quantitatively captures the observations that the induction of DSBs by 5-FU and 5-FU anabolites are candidate predictive markers of 5-FU treatment efficacy [<xref rid="pcbi.1010685.ref039" ref-type="bibr">39</xref>, <xref rid="pcbi.1010685.ref040" ref-type="bibr">40</xref>]. In addition, the TGI model is constructed and validated using literature tumor volume data observed from the tumor xenografts administered with different dosage regimens. Another advantage of our mechanistic model is that the simulation-based resistance analysis can be conducted to provide the computational assessment of the potential causes of tumor resistance to 5-FU treatment. We not only examined the role of individual reactions in causing tumor resistance to 5-FU but also took into account the interactions among multiple factors. By comparing the time courses corresponding to these simulation scenarios and the time course of the tumor volume measured in 5-FU resistant cell line, we computationally identify which events contribute significantly to the drug resistance. Furthermore, we carried out global sensitivity analysis by applying the Morris method to screen out the subsets of the parameters with considerable effects on model outputs and then applying Sobol analysis that allows for the analysis of parameter interaction effects.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><p>Our mechanism-based model is composed of PK, cellular, and tumor growth inhibition (TGI) sub-models, the last two of which constitute the PD model. The model diagram is shown in <xref rid="pcbi.1010685.g001" ref-type="fig">Fig 1</xref>. The PK model is used to compute the concentration-time profile, and the TGI model focuses on the kinetics of tumor growth post-treatment. Our cellular sub-model captures physiological processes at the molecular level and connects the drug distribution in plasma and pharmacological response towards the drug action.</p><fig position="float" id="pcbi.1010685.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.g001</object-id><label>Fig 1</label><caption><title>Schematic representation of PK, cellular and tumor growth inhibition (TGI) model.</title><p>(A) PK model; (B) Cellular and TGI model. <italic toggle="yes">A</italic><sub>1</sub>:amount of 5-FU in central plasma; <italic toggle="yes">A</italic><sub>2</sub>: amount of 5-FU in peripheral compartment; <italic toggle="yes">C</italic><sub><italic toggle="yes">p</italic></sub>(<italic toggle="yes">t</italic>): 5-FU concentration in central plasma. <italic toggle="yes">A</italic><sub>3</sub>: amount of 5-FU in interstitial fluid; <italic toggle="yes">A</italic><sub>4</sub>: amount of 5-FU in the intra-cellular domain; <italic toggle="yes">A</italic><sub>5</sub>: amount of 5-FU anabolites; <italic toggle="yes">A</italic><sub>6</sub>: incorporation of FUTP into RNA; <italic toggle="yes">A</italic><sub>7</sub>: incorporation of FdUTP into DNA; <italic toggle="yes">A</italic><sub>8</sub>: amount of dUMP;<italic toggle="yes">A</italic><sub>9</sub>: amount of TS-FdUMP complex; <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub>: amount of free TS; <italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>: amount of total TS; <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub>: extent of dNTP pool imbalance; <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>: count of 5-FU induced DSBs; <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>: deviation of 5-FU induced DSBs from baseline; <italic toggle="yes">P</italic>: amount of proliferating cells; <italic toggle="yes">D</italic>: amount of damaged cells. <italic toggle="yes">V</italic>: volumes of compartments; <inline-formula id="pcbi.1010685.e001"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e001g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e001.jpg"/><mml:math id="M1" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>: Michaelis&#8211;Menten parameters; <italic toggle="yes">Q</italic>: clearance between neighboring compartments; <italic toggle="yes">k</italic>: rate constant; <italic toggle="yes">T</italic>: delaying parameters; <italic toggle="yes">G</italic><sub>0</sub>: production rate of dUMP;; &#955;<sub><italic toggle="yes">d</italic></sub>: death rate of tumor cells without 5-FU; <italic toggle="yes">f</italic><sub><italic toggle="yes">HRR</italic></sub>: rate of repair of DSBs by HRR. <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>: measure of contribution of DSBs in producing damaged cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pcbi.1010685.g001.jpg"/></fig><sec id="sec003"><title>PK model</title><p>The PK model is described by a two-compartment plasma-peripheral model with Michaelis-Menten clearance [<xref rid="pcbi.1010685.ref008" ref-type="bibr">8</xref>, <xref rid="pcbi.1010685.ref041" ref-type="bibr">41</xref>&#8211;<xref rid="pcbi.1010685.ref043" ref-type="bibr">43</xref>]. The central compartment models the drug distribution in the central plasma. All the remaining tissue space is captured by a hypothetical compartment, referred to as the peripheral compartment so that the exchange of drug substances between central blood (compartment 1) and auxiliary region of human body (compartment 2) given by a linear kinetics, and non-linear elimination collectively describe the drug fate in the circulatory system.</p><p>The levels of 5-FU in the central plasma (<italic toggle="yes">A</italic><sub>1</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) and in the peripheral regions(<italic toggle="yes">A</italic><sub>2</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) change according to the Eqs (<xref rid="pcbi.1010685.e002" ref-type="disp-formula">1</xref>) and (<xref rid="pcbi.1010685.e003" ref-type="disp-formula">2</xref>).
<disp-formula id="pcbi.1010685.e002"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e002g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e002.jpg"/><mml:math id="M2" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>Q</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfrac><mml:msub><mml:mi>A</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:msub><mml:mi>Q</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mspace width="2pt"/><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(1)</label></disp-formula>
<disp-formula id="pcbi.1010685.e003"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e003g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e003.jpg"/><mml:math id="M3" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>Q</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:msub><mml:mi>Q</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfrac><mml:msub><mml:mi>A</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(2)</label></disp-formula>
<disp-formula id="pcbi.1010685.e004"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e004g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e004.jpg"/><mml:math id="M4" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>C</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>V</mml:mi></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(3)</label></disp-formula>
where <italic toggle="yes">Q</italic><sub>12</sub> is volume of 5-FU cleared inter-compartmentally between central and peripheral space per minute. <italic toggle="yes">V</italic><sub>1</sub> and <italic toggle="yes">V</italic><sub>2</sub> are the volumes of the central and peripheral compartments, respectively. <italic toggle="yes">V</italic><sub>max 1</sub> and <italic toggle="yes">K</italic><sub>m1</sub> describe the process of elimination of 5-FU from central plasma.</p></sec><sec id="sec004"><title>Cellular model</title><p>The cellular model is built using a compartmental modeling approach, which is one of the common techniques utilized to model biochemical pathways. In the previous model involving similar molecular complexity developed by Wolf et al [<xref rid="pcbi.1010685.ref044" ref-type="bibr">44</xref>], the drug transfer from interstitial fluid to intra-cellular space and the emergence of products of drug action are considered. In our work, we construct a model including a more detailed description of physiological events associated with 5FU cytotoxicity. The cellular model considers the 5-FU concentration in interstitial fluid (compartment 3), formation of 5-FU anabolites (compartment 5), insertion of FUTP, FdUTP into RNA and DNA (compartment 6 and 7) binding of FdUMP to TS (compartment 9), changes in the components of the dNTP pool caused by reduced TS catalytic activity (compartment 10) and DSB induction as a response to imbalanced dNTP pool (compartment 11). For the purpose of modeling, the compounds are assumed to dissolve in a spatially homogenous environment and be confined in the compartments, in which certain reactions with the respective compounds as reactants would take place. The rate of change of these reactions are represented by the influx and efflux of corresponding compartments. The dynamics of those species are subject to a group of differential equations described by the law of mass action and the Michaelis-Menten kinetics. The time evolution of physiological intermediates, as the output of the cellular model, is involved in the determination of drug effect measures, driving the ultimate pharmacodynamic responses.</p><sec id="sec005"><title>5-FU in interstitial fluid and its anabolism</title><p>The differential equations describing the evolution of 5-FU in interstitial fluid (<italic toggle="yes">A</italic><sub>3</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>), intra-cellular 5-FU (<italic toggle="yes">A</italic><sub>4</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) and 5-FU anabolites(<italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) are formulated in Eqs (<xref rid="pcbi.1010685.e005" ref-type="disp-formula">4</xref>), (<xref rid="pcbi.1010685.e006" ref-type="disp-formula">5</xref>) and (<xref rid="pcbi.1010685.e007" ref-type="disp-formula">6</xref>). The kinetics of 5-FU in interstitial fluid (<italic toggle="yes">A</italic><sub>3</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) is governed by unidirectional transmission from central plasma [<xref rid="pcbi.1010685.ref045" ref-type="bibr">45</xref>, <xref rid="pcbi.1010685.ref046" ref-type="bibr">46</xref>], first-order elimination from the extracellular domain (<italic toggle="yes">k</italic><sub>03</sub>) and update and removal of 5-FU molecule across the tumor cell membrane [<xref rid="pcbi.1010685.ref046" ref-type="bibr">46</xref>]. The influx and efflux transporters anchored on the cell membrane contribute to uptake and clearance of 5-FU drug molecules [<xref rid="pcbi.1010685.ref047" ref-type="bibr">47</xref>]. Considering that the drug diffusion into the target cell is limited by the maximum number of available uptake transporters, the Michaelis kinetics, characterized by the saturation curve, is applied to describe the process of absorption of 5-FU by tumor cells. It is difficult to detect the individual low molecular-weight 5-FU anabolites (i.e. fluoronucleotides and fluoronucleosides, denoted as FNUC) accurately despite using high precision techniques [<xref rid="pcbi.1010685.ref048" ref-type="bibr">48</xref>]. Therefore, FNUCs are collectively represented by variable <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>) and are modeled to be uniformly distributed and non-diffusing in one compartment. The rate of formation of <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>) is through 5-FU anabolism. The decomposition of the TS-FdUMP complex and removal of 5-FU from RNA account for the replenishment of <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>). The decrease of amount of <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>) is regulated by the incorporation of FdUTP and FUTP into DNA and RNA and attachment of FdUMP on TS.</p><p>The time-dependent levels of incorporated FU residues into RNA(<italic toggle="yes">A</italic><sub>6</sub>(<italic toggle="yes">t</italic>), FU-RNA, and DNA((<italic toggle="yes">A</italic><sub>7</sub>(<italic toggle="yes">t</italic>), FU-DNA) are the solution of Eqs (<xref rid="pcbi.1010685.e008" ref-type="disp-formula">7</xref>) and (<xref rid="pcbi.1010685.e009" ref-type="disp-formula">8</xref>). The influxes into compartment 6 and compartment 7 quantitatively capture the incorporation of 5-FU into RNA and DNA, receptively, the rates of which are driven by the kinetics of 5-FU anabolites (<italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>)). The efflux terms in Eqs (<xref rid="pcbi.1010685.e008" ref-type="disp-formula">7</xref>) and (<xref rid="pcbi.1010685.e009" ref-type="disp-formula">8</xref>) describe the efficiency of excision of uracil bases by cell-intrinsic repair machineries. Different from the linear kinetics for FU-RNA, Michaelis-Menten kinetics is applied to FU-DNA since FdUTP insertion into DNA and restoring FU-containing DNA is regulated by protein enzymes. According to the experimental data regarding 5-FU insertion into genomes, the process of removing genomic 5-FU is not instantaneous but rather lasts for days. It is also shown in the literature that the initiation of cell cycle checkpoint and futile cycle DNA repair are the two main causes of delayed DNA repair process. The persistence of uracil analogs in genomes challenges genomic stability, initiating the cell cycle checkpoint and preventing cell cycle progression. The cellular repair machineries are precipitously assembled. However, the futile cycling repair, the causes of which have been discussed at length in the introduction, leads to the accumulation of unrepaired mismatched bases and impeded operation of DNA repair proteins. In conformity with the underlying mechanism, the rates of loss of FU-RNA and FU-DNA are the function of past states of FU-RNA and FU-DNA, realized by two delaying parameters (<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">RNA</italic></sub>, <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub>). Specifically, for <italic toggle="yes">t</italic> &#8804; <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">RNA</italic></sub>(<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub>), the loss of genomic 5-FU in RNA(DNA) is modeled as the kinetics without delay, while, for <italic toggle="yes">t</italic> &gt; <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">RNA</italic></sub>(<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub>), the elimination of FU-RNA (FU-DNA) is considered as a process that depends on the past state of FUTP (FdUTP) insertion into RNA(DNA).</p><p>Overall, the differential equations governing the dynamics of extracellular 5-FU (<italic toggle="yes">A</italic><sub>3</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>), intra-cellular 5-FU (<italic toggle="yes">A</italic><sub>4</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>), 5-FU anabolites(<italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>), FU- RNA(<italic toggle="yes">A</italic><sub>6</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) and FU-DNA (<italic toggle="yes">A</italic><sub>7</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) are shown below.
<disp-formula id="pcbi.1010685.e005"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e005g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e005.jpg"/><mml:math id="M5" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>31</mml:mn></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mtext>efflux</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mtext>m,efflux</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mtext>influx</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mtext>m,influx</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>03</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(4)</label></disp-formula>
<disp-formula id="pcbi.1010685.e006"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e006g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e006.jpg"/><mml:math id="M6" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mtext>efflux</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mtext>m,efflux</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mtext>influx</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mtext>m,influx</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mn>54</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mtext>m,54</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(5)</label></disp-formula>
<disp-formula id="pcbi.1010685.e007"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e007g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e007.jpg"/><mml:math id="M7" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mspace width="2pt"/><mml:mn>54</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>54</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>56</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>06</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>R</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>lag,RNA</mml:mtext></mml:msub></mml:msup></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>59</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>9</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>-</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>65</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mspace width="2pt"/><mml:mn>75</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>75</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>95</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(6)</label></disp-formula>
<disp-formula id="pcbi.1010685.e008"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e008g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e008.jpg"/><mml:math id="M8" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>65</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>56</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>06</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>R</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>lag,RNA</mml:mtext></mml:msub></mml:msup></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(7)</label></disp-formula>
With <italic toggle="yes">A</italic><sub>6</sub>(<italic toggle="yes">t</italic>) = 0, for &#8722;<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">RNA</italic></sub> &#8804; <italic toggle="yes">t</italic> &#8804; 0
<disp-formula id="pcbi.1010685.e009"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e009g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e009.jpg"/><mml:math id="M9" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mn>7</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mn>75</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mn>75</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>7</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>7</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>07</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>7</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>D</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>lag,DNA</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(8)</label></disp-formula>
With <italic toggle="yes">A</italic><sub>7</sub>(<italic toggle="yes">t</italic>) = 0, for &#8722;<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub> &#8804; <italic toggle="yes">t</italic> &#8804; 0.</p><p>In which <italic toggle="yes">C</italic><sub><italic toggle="yes">p</italic></sub>(<italic toggle="yes">t</italic>) denotes concentration of 5-FU in central plasma, which is solely defined by the PK model, <italic toggle="yes">Q</italic><sub>31</sub> is the volume of 5-FU cleared from central plasma to extracellular space per unit time, <italic toggle="yes">V</italic><sub>max,influx</sub> along with <italic toggle="yes">K</italic><sub>m,influx</sub> describes the saturable uptake, <italic toggle="yes">V</italic><sub>max,efflux</sub> and <italic toggle="yes">K</italic><sub>m,efflux</sub> describe the saturable removal, <italic toggle="yes">k</italic><sub>03</sub> is the first order rate of eliminating 5-FU from interstitial fluid, <italic toggle="yes">V</italic><sub>max,54</sub> is the maximum rate of 5-FU anabolism, and <italic toggle="yes">K</italic><sub>m54</sub> is the corresponding half saturation value. <italic toggle="yes">k</italic><sub>56</sub> and <italic toggle="yes">k</italic><sub>65</sub> are the first order rates of incorporating FUTP into and removing FUTP from RNA. <italic toggle="yes">k</italic><sub>06</sub> and <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">RNA</italic></sub> as well as <italic toggle="yes">k</italic><sub>07</sub> and <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub>, describe the delayed excision of incorporated FU residues from RNA and DNA. <italic toggle="yes">&#947;</italic><sub>lag,RNA</sub> and <italic toggle="yes">&#947;</italic><sub>lag,DNA</sub> are used to adjust curve shape. The DNA polymerase with limited catalytic capability controls the insertion of FdUTP into DNA, expressed by parameters <italic toggle="yes">V</italic><sub>max,75</sub> and <italic toggle="yes">K</italic><sub>m,75</sub>. <italic toggle="yes">V</italic><sub>max,7</sub> and <italic toggle="yes">K</italic><sub>m,7</sub> represent the rate of removal of FdUTP from DNA by UNG. Initial conditions for each compartment are zero. The units of incorporation of 5-FU into DNA and RNA are fmol&#8901; <italic toggle="yes">&#956;</italic>g<sup>&#8722;1</sup> DNA and pmol&#8901; <italic toggle="yes">&#956;</italic>g<sup>&#8722;1</sup> RNA, as shown in the data source literature, which are converted to pmol&#8901; mg<sup>&#8722;1</sup> tissue through the concentration of DNA and RNA(0.2 <italic toggle="yes">&#956;</italic>g/mg tissue and 2 <italic toggle="yes">&#956;</italic>g/mg tissue respectively) [<xref rid="pcbi.1010685.ref049" ref-type="bibr">49</xref>].</p><p>The next dynamics we need to model is the binding of FdUMP to TS, which is considered to be the main contributor to 5-FU cytotoxicity. The study on analyzing the protein structure of E.coli TS [<xref rid="pcbi.1010685.ref050" ref-type="bibr">50</xref>] found that the methylation of dUMP to dTMP by TS with CH2THF as the methyl donor is a sequential process in which the dUMP binds at the active site of TS before CH2THF does. However, from the quantitative perspective, the differences in rate between the nucleotide/folate-ordered and random binding mechanism of reaction at TS is minimal [<xref rid="pcbi.1010685.ref051" ref-type="bibr">51</xref>]. Thus, for the sake of simplicity, we assume that the reaction involving dUMP is subject to rapid-equilibrium random mechanism instead of the ordered bi-substrate reaction. Since FdUMP and dUMP share the common biochemical properties in terms of covalent binding to TS [<xref rid="pcbi.1010685.ref052" ref-type="bibr">52</xref>], the pattern of interaction between FdUMP and TS is also in the manner of rapid equilibrium, demonstrated by the first term in <xref rid="pcbi.1010685.e010" ref-type="disp-formula">Eq (9)</xref>. It is also assumed that the free TS is saturated with CH2FH4.</p><p>To model the rate of TS-FdUMP complex formation, the quantity of TS enzyme over time is also considered, as shown in <xref rid="pcbi.1010685.e011" ref-type="disp-formula">Eq (10)</xref>. It is a consistent finding that the TS expression increases in response to 5-FU treatment [<xref rid="pcbi.1010685.ref053" ref-type="bibr">53</xref>&#8211;<xref rid="pcbi.1010685.ref055" ref-type="bibr">55</xref>]. TS expression at both protein and mRNA levels are regulated by multiple factors such as activation of cyclin/CDK complexes and its auto-regulatory feedback [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]. The increase in TS level after 5-FU exposure, with contributing factors still indefinite, may be related to gene amplification and disrupted synthesis regulation [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]. Therefore, it is more appropriate to estimate the total empirically content of TS by a mono-exponential equation.</p><p>Free FdUMP binding sites (<italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub>) is expressed in terms of the all available FdUMP binding sites (<italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>), and FdUMP-bound TS enzyme (TS-FdUMP). In the literature that we use as the data source, the experimental measurements of <italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub> are carried out after and <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub> are carried out before the dissociation of the ternary complex respectively [<xref rid="pcbi.1010685.ref057" ref-type="bibr">57</xref>]. Pretreatment <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub> level is set as initial level of <italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>. The amounts of <italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub> and <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub> upon exposure to 5-FU are determined by Eqs (<xref rid="pcbi.1010685.e011" ref-type="disp-formula">10</xref>) and (<xref rid="pcbi.1010685.e012" ref-type="disp-formula">11</xref>).</p><p>The kinetics of TS-FdUMP complex(<italic toggle="yes">A</italic><sub>9</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) is expressed by <xref rid="pcbi.1010685.e010" ref-type="disp-formula">Eq (9)</xref>. Eqs (<xref rid="pcbi.1010685.e011" ref-type="disp-formula">10</xref>) and (<xref rid="pcbi.1010685.e012" ref-type="disp-formula">11</xref>) are the analytical expressions for <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub> and <italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>.
<disp-formula id="pcbi.1010685.e010"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e010g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e010.jpg"/><mml:math id="M10" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>9</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>95</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>59</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>9</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>09</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>9</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(9)</label></disp-formula>
<disp-formula id="pcbi.1010685.e011"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e011g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e011.jpg"/><mml:math id="M11" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>[</mml:mo><mml:mi>&#945;</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>&#945;</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>exp</mml:mtext><mml:mo>(</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>]</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(10)</label></disp-formula>
<disp-formula id="pcbi.1010685.e012"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e012g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e012.jpg"/><mml:math id="M12" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>F</mml:mi><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(11)</label></disp-formula></p><p>In which the rate of enzyme-substrate complex formation is denoted as <italic toggle="yes">k</italic><sub>95</sub>. <italic toggle="yes">k</italic><sub>59</sub> represents the complex dissociation rate. The complex dissociation is accompanied by the release of FdUMP and the recovery of free TS. <italic toggle="yes">k</italic><sub>09</sub> represents the first-order process of complex degradation. The production rate of the TS-FdUMP complex is proportional to (<italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub> &#8722; [<italic toggle="yes">TS-dUMP</italic>]), implicating that the competition between dUMP and FdUMP on the TS nucleotide binding site impedes the attachment of FdUMP to TS. <italic toggle="yes">&#945;</italic> is the ratio of increased TS synthesis rate in the presence of drug to the normal synthesis rate of TS, <italic toggle="yes">k</italic><sub><italic toggle="yes">d</italic></sub> is the ratio of degradation rate measured in treated cells and normal degradation rate constant, <italic toggle="yes">TS</italic><sub>0</sub> is the level of TS protein prior to 5-FU administration.</p><p>It is assumed that there is an instantaneous equilibrium relationship between free <italic toggle="yes">dUMP</italic> and TS-dUMP-folate ternary complex. Therefore, the complex [<italic toggle="yes">TS-dUMP</italic>] is given by <xref rid="pcbi.1010685.e013" ref-type="disp-formula">Eq (12)</xref>.
<disp-formula id="pcbi.1010685.e013"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e013g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e013.jpg"/><mml:math id="M13" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mi>f</mml:mi></mml:msub><mml:mo>&#183;</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(12)</label></disp-formula>
where <italic toggle="yes">K</italic><sub><italic toggle="yes">dUMP</italic></sub> is the dissociation constant for the enzyme-substrate complex and is the ratio of reverse and forward rate constants.</p><p>It is more convenient to express complex [<italic toggle="yes">TS-dUMP</italic>] as a function of free TS and the total dUMP(<italic toggle="yes">dUMP</italic><sub>total</sub>) that is the sum of free dUMP and [<italic toggle="yes">TS-dUMP</italic>] complex, since the quantities of free TS and total dUMP are variables considered in the cellular model. By solving free dUMP out of total dUMP and [<italic toggle="yes">TS-dUMP</italic>], we can get the new expression for variable <italic toggle="yes">dUMP</italic><sub><italic toggle="yes">f</italic></sub> that is <inline-formula id="pcbi.1010685.e014"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e014g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e014.jpg"/><mml:math id="M14" display="inline" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>. Following this, [<italic toggle="yes">TS-dUMP</italic>] can be further expressed in terms of <italic toggle="yes">dUMP</italic><sub>total</sub> and <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub>, as shown in <xref rid="pcbi.1010685.e015" ref-type="disp-formula">Eq (13)</xref>.
<disp-formula id="pcbi.1010685.e015"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e015g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e015.jpg"/><mml:math id="M15" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mo>[</mml:mo><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(13)</label></disp-formula>
The zero order synthesis, production of dTMP catalyzed by TS and degradation influence time-amount curve of total dUMP(<italic toggle="yes">A</italic><sub>8</sub>(<italic toggle="yes">t</italic>), pmol&#8901;mg<sup>&#8722;1</sup>) (<xref rid="pcbi.1010685.e016" ref-type="disp-formula">Eq (14)</xref>).
<disp-formula id="pcbi.1010685.e016"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e016g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e016.jpg"/><mml:math id="M16" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>8</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>08</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mn>8</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(14)</label></disp-formula>
where <italic toggle="yes">G</italic><sub>0</sub> is the zero-order rate constant of dUMP synthesis. <italic toggle="yes">k</italic><sub>08</sub> is the first-order degradation rate of dUMP. <italic toggle="yes">r</italic><sub><italic toggle="yes">TS</italic></sub> represents the rate of conversion of dUMP to dTMP catalyzed by TS, which is responsible for the loss of total dUMP. The expression of <italic toggle="yes">r</italic><sub><italic toggle="yes">TS</italic></sub> is shown in <xref rid="pcbi.1010685.e017" ref-type="disp-formula">Eq (15)</xref> and is linearly dependent on the amount of dUMP/TS/folate ternary complex through the catalytic rate constant <italic toggle="yes">k</italic><sub><italic toggle="yes">cat</italic></sub>.
<disp-formula id="pcbi.1010685.e017"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e017g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e017.jpg"/><mml:math id="M17" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>8</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mtext>dUMP</mml:mtext><mml:mi>f</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>T</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(15)</label></disp-formula></p></sec><sec id="sec006"><title>dNTP pool imbalance</title><p>The perturbation of components in the DNA precursor pool (denoted as <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub>) is influenced by aggregated effects of 5-FU stimulated TS inhibition, cellular nucleotide salvage pathway, and nucleotide feedback. <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> is represented by the variation of the total amount of deoxynucleotides at a given time point versus the corresponding control level, following the same methodology as [<xref rid="pcbi.1010685.ref058" ref-type="bibr">58</xref>]. The mathematical expression for <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> is determined as <xref rid="pcbi.1010685.e018" ref-type="disp-formula">Eq (16)</xref>.
<disp-formula id="pcbi.1010685.e018"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e018g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e018.jpg"/><mml:math id="M18" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:msqrt><mml:mrow><mml:mtext>ln</mml:mtext><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>&#8712;</mml:mo><mml:mo>{</mml:mo><mml:mspace width="4pt"/><mml:mtext>all</mml:mtext><mml:mspace width="4pt"/><mml:mtext>dNTPs</mml:mtext><mml:mspace width="4pt"/><mml:mo>}</mml:mo></mml:mrow></mml:msub><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mo>&#8721;</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8712;</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mspace width="4pt"/><mml:mtext>all</mml:mtext><mml:mspace width="4pt"/><mml:mtext>dNTPs</mml:mtext><mml:mspace width="4pt"/><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mo>)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(16)</label></disp-formula>
In which <italic toggle="yes">x</italic><sub>0</sub> and <italic toggle="yes">x</italic> denote the size of each constituent of dNTP pool before and after 5-FU treatment, respectively. The initial value of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> is zero, implicating that prior to treatment there is no tendency towards unusual nucleotide biosynthesis. As the level of all dNTPs decrease or increase drastically from the baseline <italic toggle="yes">x</italic><sub>0</sub>, the perturbation measure would increase accordingly. The data used for model fitting is also converted to the measure of perturbation according to <xref rid="pcbi.1010685.e018" ref-type="disp-formula">Eq (16)</xref>.</p><p>The time profiles of <italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub> and <italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>, determined in the cellular model, are connected with changes of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> by introducing a new variable called perturbation in TS inhibition (<italic toggle="yes">TS</italic><sub><italic toggle="yes">p</italic></sub>) into this submodel. The degree of TS inhibition is evaluated by the ratio of the number of free FdUMP binding sites (<italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub>, pmol&#8901;mg<sup>&#8722;1</sup>) and the total available TS binding sites (<italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>, pmol&#8901;mg<sup>&#8722;1</sup>) [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]. <italic toggle="yes">TS</italic><sub><italic toggle="yes">p</italic></sub> is quantified as the deviation of TS inhibition measured post-treatment (<italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic></sub>/<italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic></sub>) from the normal portion of free TS levels (<italic toggle="yes">TS</italic><sub><italic toggle="yes">f</italic>0</sub>/<italic toggle="yes">TS</italic><sub><italic toggle="yes">total</italic>0</sub>) (<xref rid="pcbi.1010685.e019" ref-type="disp-formula">Eq (17)</xref>).
<disp-formula id="pcbi.1010685.e019"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e019g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e019.jpg"/><mml:math id="M19" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>f</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(17)</label></disp-formula>
With initial condition of 1, the value of <italic toggle="yes">TS</italic><sub><italic toggle="yes">p</italic></sub> varies within the range 0 to 1. <italic toggle="yes">TS</italic><sub><italic toggle="yes">p</italic></sub> vanishes when TS nucleotide binding sites is fully occupied by FdUMP.</p><p>We applied and modified the scheme previously developed by Setzer et al [<xref rid="pcbi.1010685.ref058" ref-type="bibr">58</xref>] to simulate the dNTP pool imbalance induced by 5-FU. The degree of dNTP pool imbalance is quantified based on the two assumptions: 1). The 5-FU cytotoxicity is directly related to dTTP and the alteration of dNTP is the direct and immediate product of TS inhibition; 2). Any disruption of dNTP supplies as a result of TS inhibition would impede the normal process of DNA replication. The kinetics of dNTP pool imbalance is decided by the two differential equations, one for variable <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> as discussed above and one for variable <italic toggle="yes">U</italic>. The cellular nucleotide salvage pathway is activated in the face of intra-cellular thymidine starvation caused by TS inhibition. Thus <italic toggle="yes">U</italic> is invented to describe the propensity of the cellular nucleotide salvage pathway to diminish the disturbance in the levels of constituents in the pool. The dynamics of <italic toggle="yes">U</italic> follow the pattern of a negative feedback loop (<xref rid="pcbi.1010685.e021" ref-type="disp-formula">Eq (19)</xref>). As the first terms in Eqs (<xref rid="pcbi.1010685.e020" ref-type="disp-formula">18</xref>) and (<xref rid="pcbi.1010685.e021" ref-type="disp-formula">19</xref>) show, the rates of production of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> and <italic toggle="yes">U</italic> both increase as the perturbation in TS inhibition are elevated, and finally converge to corresponding upper bounds(<italic toggle="yes">k</italic><sub>1</sub> and <italic toggle="yes">k</italic><sub>10</sub>). Therefore, as no FdUMP is attached to TS, all the binding sites on TS are available for dUMP, and the fluctuation in dNTP would return to baseline level. In addition, the collective effects of <italic toggle="yes">TS</italic><sub><italic toggle="yes">p</italic></sub>, <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> and <italic toggle="yes">U</italic> impose negative components to the rate of change of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> and are represented by the third term in <xref rid="pcbi.1010685.e020" ref-type="disp-formula">Eq (18)</xref> which is smaller for the smaller level of <italic toggle="yes">TS</italic><sub><italic toggle="yes">p</italic></sub> and larger for the greater level of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> and <italic toggle="yes">U</italic>. Besides, the second term in <xref rid="pcbi.1010685.e020" ref-type="disp-formula">Eq (18)</xref>, solely dependent on the level of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub>, describes the amelioration of disturbance by biochemical interactions among components in the dNTP pool. The kinetics of <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub> and <italic toggle="yes">U</italic> are described by the differential equations(Eqs (<xref rid="pcbi.1010685.e020" ref-type="disp-formula">18</xref>) and (<xref rid="pcbi.1010685.e021" ref-type="disp-formula">19</xref>)).
<disp-formula id="pcbi.1010685.e020"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e020g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e020.jpg"/><mml:math id="M20" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mi>U</mml:mi><mml:mo>&#183;</mml:mo><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mi>U</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:msubsup><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:msup><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>B</mml:mi></mml:msub><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(18)</label></disp-formula>
<disp-formula id="pcbi.1010685.e021"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e021g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e021.jpg"/><mml:math id="M21" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>dNTP</mml:mtext></mml:msub></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>dNTP</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>dNTP</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>9</mml:mn></mml:msub><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mi>U</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(19)</label></disp-formula></p><p>In which <italic toggle="yes">&#947;</italic><sub><italic toggle="yes">dNTP</italic></sub> is a hill parameter. All the other parameters are the unitless quantities.</p></sec><sec id="sec007"><title>DSB induction</title><p>dNTP pool imbalance and cellular repair pathways are implicated in the production and elimination of DSBs, denoted as <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) in the model. The intactness of DNA precursors in the dNTP pool partially guarantees the success of DNA biosynthesis and DNA damage repair [<xref rid="pcbi.1010685.ref032" ref-type="bibr">32</xref>]. The perturbed dNTP pool caused by TS inhibition would result in double strand DNA break during DNA replication in the S phase [<xref rid="pcbi.1010685.ref032" ref-type="bibr">32</xref>, <xref rid="pcbi.1010685.ref037" ref-type="bibr">37</xref>]. In response to the aberrant DNA duplex structure, the cell cycle checkpoints are triggered to allow the repair machinery to restore the genomic stability; if the DNA repair fails, apoptosis pathway would be activated to clear the damaged cells [<xref rid="pcbi.1010685.ref034" ref-type="bibr">34</xref>].</p><p>The literature data shows that the induction of DSBs caused by 5-FU is delayed following the occurrence of dNTP pool imbalance. Such an assumption is also biologically reasonable since the two cellular events are occurred at different molecular levels and are related to cell cycle progression. In the absence of detrimental effects of dNTP pool imbalance, the generation of severe DNA lesions depends on the zero-order rate constant <italic toggle="yes">k</italic><sub>0</sub>. The outflow term <inline-formula id="pcbi.1010685.e022"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e022g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e022.jpg"/><mml:math id="M22" display="inline" overflow="scroll"><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula> stands for the efficiency of normal DNA repair responses. Mathematically, the dynamics of DSB generation (<italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>)) for 0 &#8804; <italic toggle="yes">t</italic> &#8804; <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic></sub> is governed by <xref rid="pcbi.1010685.e023" ref-type="disp-formula">Eq (20)</xref>
<disp-formula id="pcbi.1010685.e023"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e023g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e023.jpg"/><mml:math id="M23" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(20)</label></disp-formula>
By contrast, the rate of formation of 5-FU-induced DSB depends on the past states of perturbation in dNTP pool (<italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub>) and is modeled as a full sigmoid formula so that the amount of DNA fragmentation caused by 5-FU may converge to an upper limit <italic toggle="yes">V</italic><sub>max,<italic toggle="yes">dNTP</italic></sub>. The elimination of DSB is mediated not only by DNA repair response, but also by the availability of DNA precursors [<xref rid="pcbi.1010685.ref059" ref-type="bibr">59</xref>]. It has been suggested that the polymerization of DNA in the course of homologous recombination repair (HR) is obstructed by imbalanced nucleotide pools resulting from FdUMP binding to TS [<xref rid="pcbi.1010685.ref060" ref-type="bibr">60</xref>]. Therefore, the kinetics of HR efficiency decreases as the perturbation in the dNTP pool is elevated. For <italic toggle="yes">t</italic> &gt; <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic></sub>, the dynamics of DSB induction is governed by <xref rid="pcbi.1010685.e024" ref-type="disp-formula">Eq 21</xref>.
<disp-formula id="pcbi.1010685.e024"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e024g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e024.jpg"/><mml:math id="M24" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:msup><mml:mo>&#183;</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(21)</label></disp-formula>
with <italic toggle="yes">Nuc<sub>p</sub></italic>(<italic toggle="yes">t</italic>) = 0 for &#8722;<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DSB</italic></sub> &#8804; <italic toggle="yes">t</italic> &#8804; 0.</p><p>In which the delaying effect of dNTP pool imbalance on <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) is modeled as the explicit delay parameter <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DSB</italic></sub>. <italic toggle="yes">&#947;</italic><sub><italic toggle="yes">DSB</italic></sub> is used to adjust the shape of the curve.</p><p>5-FU-mediated disturbance in genomic stability (<italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>)) is qualified on the basis of kinetics of <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) and is incorporated into the TGI model. <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>) measure deviation of the DSBs exclusively caused by dNTP pool contamination from the time-dependent baseline level, given by <xref rid="pcbi.1010685.e025" ref-type="disp-formula">Eq (22)</xref>
<disp-formula id="pcbi.1010685.e025"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e025g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e025.jpg"/><mml:math id="M25" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(22)</label></disp-formula>
In which <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>) is a unitless quantity. The time course of <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,0</sub>(<italic toggle="yes">t</italic>) is simulated based on the placebo treatment [<xref rid="pcbi.1010685.ref061" ref-type="bibr">61</xref>]. The value of <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>) is zero when no drug is administered and <inline-formula id="pcbi.1010685.e026"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e026g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e026.jpg"/><mml:math id="M26" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> is the number of DSB in the absence of any medical intervention and is varied with time as it is probable for other endogenous factors to induce DSBs to a lesser extent.</p></sec></sec><sec id="sec008"><title>Tumor growth inhibition model</title><p>The TGI model is built on the basis of the indirect response model and life span model. It is assumed that the overall tumor cell population, denoted as <italic toggle="yes">T</italic>, comprises proliferative and damaged cells. The pharmaceutical response examined in this module is the change of tumor volume(<italic toggle="yes">cm</italic><sup>3</sup>). Accordingly, the tumor growth inhibition (TGI) model is composed of the differential equations governing the kinetics of proliferating cell population (<italic toggle="yes">P</italic>(<italic toggle="yes">t</italic>)) and damaged quiescent cell population (<italic toggle="yes">D</italic>(<italic toggle="yes">t</italic>)), as shown in Eqs (<xref rid="pcbi.1010685.e027" ref-type="disp-formula">23</xref>) and (<xref rid="pcbi.1010685.e028" ref-type="disp-formula">24</xref>).
<disp-formula id="pcbi.1010685.e027"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e027g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e027.jpg"/><mml:math id="M27" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>I</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:msub><mml:mo>&#955;</mml:mo><mml:mi mathvariant="normal">g</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#183;</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>max</mml:mtext></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>-</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo><mml:msub><mml:mo>&#955;</mml:mo><mml:mi mathvariant="normal">d</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(23)</label></disp-formula>
<disp-formula id="pcbi.1010685.e028"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e028g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e028.jpg"/><mml:math id="M28" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>D</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mo>&#955;</mml:mo><mml:mi>d</mml:mi></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mo>&#955;</mml:mo><mml:mi>d</mml:mi></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mtext>d,Tv</mml:mtext></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mtext>d,Tv</mml:mtext></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mtext>d,Tv</mml:mtext></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(24)</label></disp-formula>
<disp-formula id="pcbi.1010685.e029"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e029g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e029.jpg"/><mml:math id="M29" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(25)</label></disp-formula>
<disp-formula id="pcbi.1010685.e030"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e030g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e030.jpg"/><mml:math id="M30" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>D</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(26)</label></disp-formula></p><p>Where <italic toggle="yes">T</italic><sub>d,Tv</sub> is the mean life span of damaged cells. Cells <italic toggle="yes">D</italic> would be processing the damage for <italic toggle="yes">T</italic><sub>d,Tv</sub> until they are eliminated from the entire tumor cell population. <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>) is amount 5-FU anabolites at time <italic toggle="yes">t</italic>, computed in cellular model. <italic toggle="yes">IC</italic><sub>50</sub> is the concentration of 5-FU anabolites that causes the 50% decrease in tumor proliferation rate. <italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub> is the maximal fractional factor of DSB-induced stimulatory effect on the production of damaged quiescent cells. <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub> is the level of <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub> necessary to produce the half-maximal stimulatory effect. &#955;<sub><italic toggle="yes">g</italic></sub> is the tumor growth rate. &#955;<sub><italic toggle="yes">d</italic></sub> is the natural death rate. <italic toggle="yes">P</italic><sub>max</sub> is the carrying capacity of tumor growth. <italic toggle="yes">&#947;</italic><sub>Tv</sub> is a curve-adjusting parameter, whose value is fixed as 0.2. The initial value of <italic toggle="yes">P</italic>(<italic toggle="yes">t</italic>) is the last measurement of tumor volumes before administration starts, while the initial value of <italic toggle="yes">D</italic>(t) is zero.</p><p>The TGI model incorporates two mechanistic components, 5-FU anabolites and 5-FU induced DSBs to account for the inhibition of tumor proliferation by 5-FU treatment. Their individual effects on the pharmacological responses are mathematically formulated by full sigmoid <italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub> model, giving rise to <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) (<xref rid="pcbi.1010685.e031" ref-type="disp-formula">Eq (27)</xref>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) (<xref rid="pcbi.1010685.e032" ref-type="disp-formula">Eq (28)</xref>)
<disp-formula id="pcbi.1010685.e031"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e031g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e031.jpg"/><mml:math id="M31" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>I</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(27)</label></disp-formula>
whose value is subject to the upper limit of 1. The smaller the value of <italic toggle="yes">IC</italic><sub>50</sub>, the more responsive tumor cells would be to the suppressive effects imposed by 5-FU anabolites.</p><p>Likewise, <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>) is presumed to enhance the loss of proliferative cells with the rate given by <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>)
<disp-formula id="pcbi.1010685.e032"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e032g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e032.jpg"/><mml:math id="M32" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(28)</label></disp-formula>
The maximum allowable value of <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) is <italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub>. <italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub>, <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub> and <italic toggle="yes">IC</italic><sub>50</sub> are drug-sensitivity parameters and modulate the potency of the chemotherapy.</p><p>Two different scenarios associated with the TGI model are discussed in detail.</p><list list-type="order"><list-item><p>Tumor dynamics in the absence of drug intervention</p><p>The dynamics of proliferative cells in the absence of drug intervention is mediated by <xref rid="pcbi.1010685.e033" ref-type="disp-formula">Eq (29)</xref>.
<disp-formula id="pcbi.1010685.e033"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e033g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e033.jpg"/><mml:math id="M33" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#955;</mml:mo><mml:mi mathvariant="normal">g</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#183;</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>max</mml:mtext></mml:msub></mml:mfrac><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mo>&#955;</mml:mo><mml:mi mathvariant="normal">d</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(29)</label></disp-formula>
In normal circumstances, the proliferative tumor cells would grow according to the logistic model and naturally shrink according to the rate constant &#955;<sub>d</sub>. Linear constant &#955;<sub><italic toggle="yes">d</italic></sub> regulates the rate of the conversion from the proliferating cells to dead cells which is not affected by chemotherapy. Since in this case, there is no extra DSBs that are triggered by 5-FU treatment, the term (<inline-formula id="pcbi.1010685.e034"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e034g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e034.jpg"/><mml:math id="M34" display="inline" overflow="scroll"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mtext>Tv</mml:mtext></mml:msub></mml:msup></mml:mrow></mml:mfrac><mml:mrow/></mml:mrow></mml:math></alternatives></inline-formula>) is zero, meaning that no damaged cells emerge from normally cycling cell population. Taken together, the three parameters &#955;<sub><italic toggle="yes">g</italic></sub>, <italic toggle="yes">P</italic><sub>max</sub>, &#955;<sub>d</sub> outline the tumor growth pattern in the absence of medical intervention.</p></list-item><list-item><p>Treatment responses</p><p>With 5-FU treatment, the tumor progression is assumed to be subject to 5-FU anabolites and DSBs induced by the perturbed dNTP pool. The effects of two quantities are modeled as hill functions and serve as system biomeasures driving tumor dynamics, as shown in <xref rid="pcbi.1010685.e028" ref-type="disp-formula">Eq (24)</xref>. The biochemical reactions mediated by 5-FU anabolites result in abnormality in DNA replication and repair, leading to the incomplete preparation for cell division. Such feature is reflected by the term <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) that is in inverse proportion to the concentration of 5-FU anabolites. Besides, as a contributory factor in 5-FU cytotoxicity, 5-FU-induced DSBs are responsible for the production of damaged cells with a rate <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>). Therefore, in our model design, the increase of quiescent tumor cells is driven by the irreversible transition from proliferative tumor cells instead of their proliferation. The tumor cells that incur DSB lesions are not deemed to be eliminated from the entire tumor cell population instantaneously after the onset of DSB, and yet they would undergo progressive stages of damage before they die, which is biologically plausible since the processing of DSB is related with time-dependent signal cascades regulating cell cycle progression. To that end, the life span model, as reviewed in literature [<xref rid="pcbi.1010685.ref062" ref-type="bibr">62</xref>, <xref rid="pcbi.1010685.ref063" ref-type="bibr">63</xref>], is implemented to capture the elongated survival time of non-growing cells. As components of the life span model scheme, the delay differential equation (DDE) is incorporated in the TGI model and describes the delayed onset of the observed drug effects. <italic toggle="yes">T</italic><sub>d,Tv</sub> denotes the mean transit time through all the damage stages for <italic toggle="yes">P</italic>(<italic toggle="yes">t</italic>). Therefore, in the case of 5-FU treatment, the alterations of variable <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>), <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>) directly change the dynamics of tumor growth. The damaged cells would emerge once 5-FU induced DSB is above the baseline value <inline-formula id="pcbi.1010685.e035"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e035g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e035.jpg"/><mml:math id="M35" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. Between the two consecutive doses, <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>) are expected to return to zero and the change in tumor volume would then become a function of &#955;<sub><italic toggle="yes">g</italic></sub>, <italic toggle="yes">P</italic><sub>max</sub>, &#955;<sub>d</sub>, claiming the pattern of unperturbed tumor growth. Besides, the rate constant of tumor natural death and the baseline rate of irreversible conversion from the proliferative to quiescent cells are assumed to be equal to&#955;<sub><italic toggle="yes">d</italic></sub>.</p></list-item></list></sec><sec id="sec009"><title>Model implementation and Parameter estimation</title><p>We utilized the Bayesian inference method to estimate the expected values of the model parameters as the Bayesian inference can capture the uncertainty of model parameters given the experimental data. Specifically, the Markov chain Monte Carlo (MCMC) technique is applied to obtain the approximated expected values. In order to address the computational intensity and the difficulty of convergence of the posterior distributions when the model parameters are estimated simultaneously, we conducted the parameter estimations in a sequential manner as follows: We fitted the model parameters of the plasma concentration first and fixed the parameter values as the means of the samples generated by the MCMC technique to estimate the parameters defined in the cellular model. In a similar way, the expected values of cellular model parameters were fixed for fitting of the TGI model. Accordingly, the model parameters are collected in four disjoint sets, denoted as <bold>&#920;</bold><sub><bold><italic toggle="yes">i</italic></bold></sub>, <italic toggle="yes">i</italic> = 1&#8230;4. Specifically, <bold>&#920;</bold><sub><bold>1</bold></sub> stands for the set of PK parameters; <bold>&#920;</bold><sub><bold>2</bold></sub> represents the set of parameters regulating the kinetics of variables ranging from <italic toggle="yes">A</italic><sub>3</sub> (5-FU in the interstitial fluid) to <italic toggle="yes">A</italic><sub>9</sub>(TS-FdUMP complex); <bold>&#920;</bold><sub>3</sub> represents the set of the parameters in the ODE equations for <italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub>, and <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>. <bold>&#920;</bold><sub><bold>4</bold></sub> represents the parameters in the TGI model. The posterior distribution is formulated by the product of the likelihood function and the prior distribution. The likelihood function is expressed through the additive noise model describing the difference between the observed value of the model variables and their predictions. The likelihood function for estimating the parameters in the parameter set &#920;<sub><italic toggle="yes">i</italic></sub>, <italic toggle="yes">i</italic> = 1&#8230;4 is calculated as <xref rid="pcbi.1010685.e036" ref-type="disp-formula">Eq (30)</xref>:
<disp-formula id="pcbi.1010685.e036"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e036g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e036.jpg"/><mml:math id="M36" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>&#8739;</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>&#8719;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mi mathvariant="bold-italic">j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8739;</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>&#8719;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mfrac><mml:mn>1</mml:mn><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mi>&#960;</mml:mi><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac><mml:mtext>exp</mml:mtext><mml:mo>(</mml:mo><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">f</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mi mathvariant="bold-italic">j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mi mathvariant="bold-italic">j</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(30)</label></disp-formula>
where <inline-formula id="pcbi.1010685.e037"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e037g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e037.jpg"/><mml:math id="M37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8230;</mml:mo><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8230;</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8712;</mml:mo><mml:msup><mml:mi mathvariant="double-struck">R</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> represents the time series data of the <italic toggle="yes">j</italic> th model variable(denoted as <italic toggle="yes">R</italic><sub><italic toggle="yes">ij</italic></sub>) whose kinetics are governed by the parameters in <bold>&#920;</bold><sub><bold><italic toggle="yes">i</italic></bold></sub>. The difference between each measurement and model prediction of <italic toggle="yes">R</italic><sub><italic toggle="yes">ij</italic></sub> is described by the measurement noise <italic toggle="yes">&#949;</italic><sub><italic toggle="yes">ij</italic></sub>. We assumed that <italic toggle="yes">&#949;</italic><sub><italic toggle="yes">ij</italic></sub> are independent random variables and normally distributed with zero mean and the variance <inline-formula id="pcbi.1010685.e038"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e038g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e038.jpg"/><mml:math id="M38" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula>. Instead of keeping <italic toggle="yes">&#949;</italic><sub><italic toggle="yes">ij</italic></sub> constant, we treated them as random variables whose marginal distributions can be learned from the data. <inline-formula id="pcbi.1010685.e039"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e039g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e039.jpg"/><mml:math id="M39" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">f</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mi mathvariant="bold-italic">j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#8712;</mml:mo><mml:msup><mml:mi mathvariant="double-struck">R</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> represents the simulated time course of <italic toggle="yes">j</italic> th variable using the parameter set <bold>&#920;</bold><sub><italic toggle="yes">i</italic></sub>. The choice of the prior distribution for each model parameter is listed in the Supporting Information <xref rid="pcbi.1010685.s003" ref-type="supplementary-material">S3 Text</xref>. It is assumed that all the parameters are random variables and are independent of each other. Thus, the joint posterior distribution of the model parameters in the parameter set <bold>&#920;</bold><sub><italic toggle="yes">i</italic></sub>, <italic toggle="yes">i</italic> = 1&#8230;4 can be determined by <xref rid="pcbi.1010685.e040" ref-type="disp-formula">Eq (31)</xref>.
<disp-formula id="pcbi.1010685.e040"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e040g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e040.jpg"/><mml:math id="M40" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>&#960;</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>&#8739;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>&#8733;</mml:mo><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8739;</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>&#960;</mml:mi><mml:mo>(</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>&#960;</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>&#8733;</mml:mo><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8739;</mml:mo><mml:msub><mml:mo mathvariant="bold">&#920;</mml:mo><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">&#963;</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:munderover><mml:mo>&#8719;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mi>&#960;</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:munderover><mml:mo>&#8719;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mi>&#960;</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(31)</label></disp-formula>
where <italic toggle="yes">m</italic><sub><italic toggle="yes">i</italic></sub> represents the number of parameters in <bold>&#920;</bold><sub><bold><italic toggle="yes">i</italic></bold></sub>. We used the robust adaptive Metropolis algorithm(RAM) [<xref rid="pcbi.1010685.ref064" ref-type="bibr">64</xref>] as the MCMC technique. The mean values of the estimated parameters together with the credible regions for each parameter are listed in <xref rid="pcbi.1010685.t001" ref-type="table">Table 1</xref>. The histograms of the estimated posterior distributions for the model parameters are provided in the Supporting Information <xref rid="pcbi.1010685.s003" ref-type="supplementary-material">S3 Text</xref>.</p><table-wrap position="float" id="pcbi.1010685.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t001</object-id><label>Table 1</label><caption><title>Parameter estimates for PK and cellular model.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t001g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t001.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Unit</th><th align="left" rowspan="1" colspan="1">Posterior mean(<italic toggle="yes">q</italic><sub>0.25</sub>,<italic toggle="yes">q</italic><sub>0.75</sub>)</th><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Unit</th><th align="left" rowspan="1" colspan="1">Posterior mean(<italic toggle="yes">q</italic><sub>0.25</sub>,<italic toggle="yes">q</italic><sub>0.75</sub>)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">
<bold>PK model</bold>
</td><td align="left" colspan="3" rowspan="1">
<bold>Cellular model</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>max</sub>
</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">&#956;</italic> g&#8901;mL<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">329.539(313.795,346.084)</td><td align="left" colspan="3" rowspan="1">&#8195;<bold>TS inhibition</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Q</italic>
<sub>21</sub>
</td><td align="left" rowspan="1" colspan="1">mL&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">320.071(39.926,680.584)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>95</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.038(0.035,0.043)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>1</sub>
</td><td align="left" rowspan="1" colspan="1">mL&#8901; (mg tissue)<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">16823.472(15776.621,18123.180)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>59</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">2.882(2.877,2.888)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>2</sub>
</td><td align="left" rowspan="1" colspan="1">mL&#8901; (mg tissue)<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">2999.821(2715.355,3266.188)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>09</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.152(0.138,0.171)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub>
</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">&#956;</italic> g&#8901; mL<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">17334.977(16261.304,18220.139)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub><italic toggle="yes">dUMP</italic></sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">21.935(21.932,21.938)</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>Cellular model</bold>
</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">G</italic><sub>0</sub></td><td align="left" rowspan="1" colspan="1">mg&#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.155(0.131,0.185)</td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;<bold>5-FU in interstitial fluid and its anabolism</bold></td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>cat</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">17.430(17.419,17.444)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Q</italic><sub>31</sub></td><td align="left" rowspan="1" colspan="1">mL&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.981(0.915,1.033)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>08</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.032(0.021,0.044)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,influx</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">538.451(537.306,539.436)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&#945;</italic><sub><italic toggle="yes">TS</italic></sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">2.021</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub>m,influx</sub></td><td align="left" rowspan="1" colspan="1">mL&#8901; (mg tissue)<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">171.153(170.931,171.378)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub><italic toggle="yes">d</italic></sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">1.034</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,efflux</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">536.642(536.044,537.006)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">TS</italic><sub>0</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">1.860e-2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub>m,efflux</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">6.704(6.571,6.829)</td><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e041"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e041g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e041.jpg"/><mml:math id="M41" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">0.203(0.199,0.207)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>03</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">135.995(134.929,137.845)</td><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e042"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e042g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e042.jpg"/><mml:math id="M42" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">2(1.9999,2.0001)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,54</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">27.138(26.149,28.348)</td><td align="left" colspan="3" rowspan="1">&#8195;<bold>dNTP pool imbalance</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub>m,54</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">2325.154(2324.075,2326.215)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>1</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.213(0.211,0.215)</td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;<bold>5-FU incorporation into DNA and RNA</bold></td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>2</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">32.50(32.49,32.51)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>65</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.089(0.082,0.096)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>3</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">3.713(3.711,3.714)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>56</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.521(0.518,0.525)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>4</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">73.389(73.368,73.409)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>06</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.114(0.111,0.119)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>5</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">3.695(3.682,3.705)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&#947;</italic><sub>lag,RNA</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.310(0.299,0.326)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>6</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.303(0.302,0.305)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,75</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.0199(0.0171,0.0223)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>7</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">3.339(3.334,3.345)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub>m,75</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.8398(0.8344,0.8467)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>8</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">1.382(1.375,1.387)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,57</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901;mg<sup>&#8722;1</sup> &#8901;min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">5.534(5.525,5.542)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>9</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.27672(0.27663,0.27684)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub>m,57</sub></td><td align="left" rowspan="1" colspan="1">pmol&#8901; mg<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.95908(0.95894,0.95922)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub><italic toggle="yes">B</italic></sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">35.65(35.63,35.67)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>07</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.808(0.796,0.819)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub><italic toggle="yes">A</italic></sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">6.038(6.022,6.054)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&#947;</italic><sub>lag,DNA</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.554(0.549,0.560)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>10</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.0794(0.0789,0.08)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">RNA</italic></sub></td><td align="left" rowspan="1" colspan="1">day</td><td align="left" rowspan="1" colspan="1">0.396(0.363,0.428)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&#947;</italic><sub>dNTP</sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">1.500e-1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub></td><td align="left" rowspan="1" colspan="1">day</td><td align="left" rowspan="1" colspan="1">4.360(4.344,4.378)</td><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e043"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e043g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e043.jpg"/><mml:math id="M43" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">0.013(0.0068,0.0158)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e044"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e044g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e044.jpg"/><mml:math id="M44" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">199.9999(199.9888,200.0107)</td><td align="left" colspan="3" rowspan="1">&#8195;<bold>DSB induction</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e045"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e045g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e045.jpg"/><mml:math id="M45" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">200.004(199.974,200.033)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,<italic toggle="yes">dNTP</italic></sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">10.516(10.515,10.519)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e046"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e046g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e046.jpg"/><mml:math id="M46" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>N</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">2.009(1.996,2.022)</td><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">V</italic><sub>max,<italic toggle="yes">HR</italic></sub></td><td align="left" rowspan="1" colspan="1">Thousands count/min</td><td align="left" rowspan="1" colspan="1">10.082(10.072,10.087)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">K</italic><sub><italic toggle="yes">m</italic>,<italic toggle="yes">HR</italic></sub></td><td align="left" rowspan="1" colspan="1">Thoudands count</td><td align="left" rowspan="1" colspan="1">194.020(194.014,194.028)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub><italic toggle="yes">i</italic></sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">0.121(0.112,0.129)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">k</italic><sub>0</sub></td><td align="left" rowspan="1" colspan="1">min<sup>&#8722;1</sup></td><td align="left" rowspan="1" colspan="1">2.803(2.789,2.815)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&#947;</italic><sub><italic toggle="yes">DSB</italic></sub></td><td align="left" rowspan="1" colspan="1">a</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8195;<italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DSB</italic></sub></td><td align="left" rowspan="1" colspan="1">Day</td><td align="left" rowspan="1" colspan="1">1.801(1.800,1.802)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8195;<inline-formula id="pcbi.1010685.e047"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e047g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e047.jpg"/><mml:math id="M47" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula></td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">199.9999(199.9995,200.0003)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>a: unitless parameter</p></fn><fn id="t001fn002"><p>b: variance of the measurement noise.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><sec id="sec011"><title>Model construction</title><sec id="sec012"><title>PK model</title><p>The PK model is composed of central and peripheral compartments. The parameters in the PK model are determined by fitting the model to the plasma concentration data measured on animal models injected with a single 100 mg/kg 5-FU dose [<xref rid="pcbi.1010685.ref065" ref-type="bibr">65</xref>]. To maintain unit consistency throughout the integrated model, the unit of 5-FU plasma concentration is converted to a molarity concentration unit <italic toggle="yes">pmol</italic>/<italic toggle="yes">mL</italic> from <italic toggle="yes">&#956;g</italic>/<italic toggle="yes">mL</italic> via the molar mass of 5-FU(130.077 g/mol). The time course of 5-FU in the peripheral compartment is estimated from the PK data. The parameter estimates are shown in <xref rid="pcbi.1010685.t001" ref-type="table">Table 1</xref> and simulated concentration-time curves for compartments 1 and 2 are shown in <xref rid="pcbi.1010685.g002" ref-type="fig">Fig 2</xref>. From the result of parameter estimation, the estimated volume of the central compartment is smaller than that of the peripheral compartment, which agrees with the estimation results shown in the previous PK/PD study [<xref rid="pcbi.1010685.ref020" ref-type="bibr">20</xref>]. The elimination phase of the peripheral compartment is slower than that of the central compartment.</p><fig position="float" id="pcbi.1010685.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.g002</object-id><label>Fig 2</label><caption><title>Model simulation of 5-FU concentration in central and peripheral compartment.</title><p>Blue solid circle represents literature data; red solid curve, time profile of 5-FU in central plasma; yellow dash-dotted curve, the time profile of 5-FU in peripheral compartment. black dashed line: 0.7 credible regions of model simulation of central compartment; black dotted line: 0.7 credible regions of model simulation of peripheral compartment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pcbi.1010685.g002.jpg"/></fig></sec><sec id="sec013"><title>Cellular model</title><p>The cellular model is composed of 5-FU concentration in interstitial fluid (<xref rid="pcbi.1010685.e005" ref-type="disp-formula">Eq (4)</xref>), intra-cellular 5-FU(<xref rid="pcbi.1010685.e006" ref-type="disp-formula">Eq (5)</xref>) formation of 5-FU anabolites (<xref rid="pcbi.1010685.e007" ref-type="disp-formula">Eq (6)</xref>, insertion of FUTP, FdUTP into RNA and DNA (Eqs (<xref rid="pcbi.1010685.e008" ref-type="disp-formula">7</xref>) and (<xref rid="pcbi.1010685.e009" ref-type="disp-formula">8</xref>)), binding of FdUMP to TS (<xref rid="pcbi.1010685.e010" ref-type="disp-formula">Eq (9)</xref>) and dUMP (<xref rid="pcbi.1010685.e016" ref-type="disp-formula">Eq (14)</xref>), perturbed dNTP pool caused by reduced TS catalytic activity (<xref rid="pcbi.1010685.e020" ref-type="disp-formula">Eq (18)</xref>) and DSB induction (<xref rid="pcbi.1010685.e021" ref-type="disp-formula">Eq (19)</xref>), whose trajectories are expressed by the solutions of the differential equations. The parameters in the cellular model are estimated by fitting to data measured on colon xenograft tumors. The literature data sources are enumerated in <xref rid="pcbi.1010685.t002" ref-type="table">Table 2</xref> and the parameter estimates are provided in <xref rid="pcbi.1010685.t001" ref-type="table">Table 1</xref>. The initial values of the variables are derived from literature data, that is the content of species at 0 h upon exposure to 5-FU. Instead of fitting to literature deta, the time course of <italic toggle="yes">A</italic><sub>3</sub>(<italic toggle="yes">t</italic>) is estimated dependent on the fluxes between compartment 3 and the neighboring measurable quantities.</p><table-wrap position="float" id="pcbi.1010685.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t002</object-id><label>Table 2</label><caption><title>Literature data for the model variables.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t002g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t002.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Moleuclar species</th><th align="left" rowspan="1" colspan="1">Model variable</th><th align="left" rowspan="1" colspan="1">Data source</th><th align="left" rowspan="1" colspan="1">Experiment</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Route of adiministration</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">5-FU in plasma</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>1</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref065" ref-type="bibr">65</xref>]</td><td align="left" rowspan="1" colspan="1">in vivio, C57/BL6 mice bearing colon 38 tumors</td><td align="left" rowspan="1" colspan="1">100 mg/kg</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">intracellular 5-FU</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>3</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref066" ref-type="bibr">66</xref>]</td><td align="left" rowspan="1" colspan="1">in vivo, Female C57BL/6 mice 8 bearing C38 murine colon tumor</td><td align="left" rowspan="1" colspan="1">115 mg/kg.</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">5-FU anabolites</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>4</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref066" ref-type="bibr">66</xref>]</td><td align="left" rowspan="1" colspan="1">in vivo, Female C57BL/6 mice 8 bearing C38 murine colon tumor</td><td align="left" rowspan="1" colspan="1">115 mg/kg.</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">FUTP incorpoartion into RNA</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>6</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref067" ref-type="bibr">67</xref>]</td><td align="left" rowspan="1" colspan="1">in vivo, Female BALB/c mice bearing colon 26-B tumor</td><td align="left" rowspan="1" colspan="1">80 mg/kg</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">FdUTP incorporation into DNA</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>7</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref068" ref-type="bibr">68</xref>]</td><td align="left" rowspan="1" colspan="1">in vitro, Colon26-B tumors</td><td align="left" rowspan="1" colspan="1">80 mg/kg</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">TS-dUMP</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>9</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref057" ref-type="bibr">57</xref>]</td><td align="left" rowspan="1" colspan="1">in vivo, Male and female Wistar rats bearing dimethylhydrazine (DMH)-induced colon carcinoma</td><td align="left" rowspan="1" colspan="1">100 mg/kg</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">Total TS</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">TS</italic>
<sub>
<italic toggle="yes">total</italic>
</sub>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref057" ref-type="bibr">57</xref>]</td><td align="left" rowspan="1" colspan="1">in vivo, Male and female Wistar rats bearing dimethylhydrazine (DMH)-induced colon carcinoma</td><td align="left" rowspan="1" colspan="1">100 mg/kg</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">dUMP</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">A</italic><sub>9</sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref069" ref-type="bibr">69</xref>]</td><td align="left" rowspan="1" colspan="1">in vivo, BALB/c mice bearing colon tumor 06/A</td><td align="left" rowspan="1" colspan="1">80 mg/kg</td><td align="left" rowspan="1" colspan="1">IP injection</td></tr><tr><td align="left" rowspan="1" colspan="1">dNTP pool</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">Nuc</italic><sub><italic toggle="yes">p</italic></sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref070" ref-type="bibr">70</xref>]</td><td align="left" rowspan="1" colspan="1">in vitro, L5178 lymphoma cells</td><td align="left" rowspan="1" colspan="1">1 <italic toggle="yes">&#956;</italic>M</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">DSB</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>)</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref061" ref-type="bibr">61</xref>]</td><td align="left" rowspan="1" colspan="1">in vitro, myeloid leukemia (OCI-AML2) cells</td><td align="left" rowspan="1" colspan="1">3<italic toggle="yes">&#956;mol</italic>/L</td><td align="left" rowspan="1" colspan="1">-</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>a: unitless parameter</p></fn><fn id="t002fn002"><p>b: variance of the measurement noise.</p></fn></table-wrap-foot></table-wrap><p>As shown in the model simulations (<xref rid="pcbi.1010685.g003" ref-type="fig">Fig 3C</xref>), the accumulation of 5-FU anabolites begins within minutes upon exposure to 5-FU, subsequent to the transmission of 5-FU from interstitial fluid to intra-cellular space. The model is able to capture the sharp decrease of non FdUMP bound TS enzyme in parallel to a rapid increase in dUMP, indicating pronounced inhibition of TS activity. In <xref rid="pcbi.1010685.g003" ref-type="fig">Fig 3F and 3G</xref>, it can be observed that the peak of dUMP amount and the lowest level of free TS enzyme coincide at roughly 5 hours after 5-FU administration, after which the decline in dUMP is accompanied by the restoration of free TS. In terms of 5-FU incorporation into the DNA, as demonstrated in both model simulation (<xref rid="pcbi.1010685.g003" ref-type="fig">Fig 3D and 3E</xref>) and literature data, the fraction of FU-RNA is higher than that of FU-DNA. Such a phenomenon may be related to the fact that RNA replication happens all the time in the cell while DNA replication only happens in the S phase. In addition, the duration of incorporation of 5-FU in RNA and DNA is longer than that of other substances, which can be explained by the involvement of cell cycle kinetics in regulating the genomic activity. <xref rid="pcbi.1010685.g003" ref-type="fig">Fig 3I</xref> depicting the formation of DNA lesions caused by 5-FU shows that in the early stages following the 5-FU administration, DSBs are maintained at a certain level before their count noticeably increase after approximately 40 hours and ultimately reaches an equilibrium state. In comparison with the timing of onset of other species, the appearance of 5-FU-induced DNA fragmentation is delayed, because 5FU can only exert anti-tumor effects when DNA replication takes place. By visually comparing <xref rid="pcbi.1010685.g003" ref-type="fig">Fig 3G and 3H</xref>, we also noticed that the maximum values of dNTP pool imbalance and 5-FU-induced DSB are reached asynchronously, in terms with the observations shown in the experimental studies focusing on the impacts of dNTP pools on the generation of lethal DNA damage and cell fate [<xref rid="pcbi.1010685.ref037" ref-type="bibr">37</xref>]. However, the time elapsed between the peak of dNTP pool imbalance and the generation of 5-FU-initiated DSB may be different if the model is fit to distinct colon cell lines with differential growth pattern and initial cell cycle phase. The histograms of the cellular model parameters are given in the Supporting Information <xref rid="pcbi.1010685.s003" ref-type="supplementary-material">S3 Text</xref>. We classified the parameters into identifiable and unidentifiable groups according to the compactness of the supports and shapes of their distributions. As shown in Fig B and Fig C in Supporting Information <xref rid="pcbi.1010685.s003" ref-type="supplementary-material">S3 Text</xref>, most of the parameters apart from <italic toggle="yes">Q</italic><sub>31</sub>, <italic toggle="yes">K</italic><sub><italic toggle="yes">m</italic>,<italic toggle="yes">influx</italic></sub>, <italic toggle="yes">k</italic><sub>63</sub>, <italic toggle="yes">&#947;</italic><sub><italic toggle="yes">lag</italic>,<italic toggle="yes">DNA</italic></sub>, <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">DNA</italic></sub>, <italic toggle="yes">k</italic><sub>95</sub>, <italic toggle="yes">k</italic><sub>59</sub>, <italic toggle="yes">G</italic><sub>0</sub>, <italic toggle="yes">k</italic><sub><italic toggle="yes">cat</italic></sub>, <italic toggle="yes">k</italic><sub>3</sub>, <italic toggle="yes">k</italic><sub>4</sub>, <italic toggle="yes">k</italic><sub>5</sub>, <italic toggle="yes">k</italic><sub><italic toggle="yes">B</italic></sub>, and <italic toggle="yes">k</italic><sub><italic toggle="yes">A</italic></sub>, <italic toggle="yes">k</italic><sub><italic toggle="yes">i</italic></sub> are identifiable.</p><fig position="float" id="pcbi.1010685.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.g003</object-id><label>Fig 3</label><caption><title>Time profiles of intermediate components in cellular model.</title><p>(A) 5-FU in interstitial fluid, (B) intra-cellular 5-FU, (C) 5-FU anabolites, (D) F-RNA, (E) F-DNA, (F) % Free TS, (G) dUMP, (H) dNTP pool imbalance, (I) double-strand break generation. Red curve, model simulation; solid blue circle, literature data points; and error bar represents standard errors. The shaded areas represent the 0.7 credible regions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pcbi.1010685.g003.jpg"/></fig></sec><sec id="sec014"><title>Tumor growth inhibition model</title><p>We applied the mechanistic PK/PD model to the dosage regimens shown in <xref rid="pcbi.1010685.t003" ref-type="table">Table 3</xref> to probe the alteration in the dose-related parameters as the changes of doses and injection schedules. The parameters in PK and cellular model are kept the same as the ones obtained from colon xenograft tumors given a single 100 mg/kg 5-FU. The initial values of 5-FU in central plasma are varied according to the dosing schemes. The PK model is reloaded at the frequency of dose administration. The parameters describing the kinetics of control groups are estimated for all the dose regimes whose data are from various sources in the literature, keeping the same value for <italic toggle="yes">&#947;</italic><sub><italic toggle="yes">Tv</italic></sub>. The <xref rid="pcbi.1010685.g004" ref-type="fig">Fig 4</xref> demonstrates that the model simulations using the mean parameter estimates shown in <xref rid="pcbi.1010685.t004" ref-type="table">Table 4</xref> are consistent with the tumor volume dynamics in literature data. Moreover, due to the lack of repeated experimental measurements from the plasma-treated (PBS) control groups, the zero net growth rate around the maximum level is assumed, indicating that the model parameterization could not explain tumor growth above the equilibrium. As the drug effect wears off, the tumor volume would eventually approach an asymptote equal to <italic toggle="yes">P</italic><sub>max</sub>, the value of which is directly estimated from the time series data with the limited duration. For dosage regimens (1), (2), (3), (5), the parameters in the TGI model are estimated by fitting the literature data, forming models (1), (2), (3), (5). Following this, the parameter estimates for the TGI model 3 are reused on protocols (4), (6), and (7) except for the drug-irrelevant parameters, considering that they have the same amount of single dose and similar dosing schedules. The estimated value of <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">Tv</italic></sub> from model (3) is also applied to models (8) and (9). On the other hand, the estimation of TGI parameters except for <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,<italic toggle="yes">Tv</italic></sub> for the protocols (8) and (9) are carried out separately due to their unique dosing structures and type of cell line. Besides, the parameters governing normal tumor growth pattern (i.e. &#955;<sub><italic toggle="yes">d</italic></sub>, <italic toggle="yes">P</italic><sub>max</sub>, &#955;<sub><italic toggle="yes">g</italic></sub>) are estimated for each protocol since the experimental data for each protocol is from a different study in the literature, and is subject to the characteristics of the cell lines and progression phases of the xenograft tumors. The control group data is used to characterize the parameters &#955;<sub><italic toggle="yes">d</italic></sub>, <italic toggle="yes">P</italic><sub>max</sub>, &#955;<sub><italic toggle="yes">g</italic></sub>. The literature tumor volume data are normalized to the respective starting values. It is also assumed that for each model, the first doses are injected at 0 h after the treatment course begins.</p><fig position="float" id="pcbi.1010685.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.g004</object-id><label>Fig 4</label><caption><title>Time-dependent outputs of the 9 TGI model using parameter estimates shown in <xref rid="pcbi.1010685.t004" ref-type="table">Table 4</xref>.</title><p>Red line represents the time course of the control group; blue line represents the time course of colon tumor growth treated with corresponding dosage regimens shown in <xref rid="pcbi.1010685.t003" ref-type="table">Table 3</xref>; triangle, literature data for the control group; circle, literature data for the treated group; error bar, standard errors; asterisk on x-axis represents injection time. The shaded areas in each panel represent the 0.7 credible intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pcbi.1010685.g004.jpg"/></fig><table-wrap position="float" id="pcbi.1010685.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t003</object-id><label>Table 3</label><caption><title>The nine different dosage regimens that are evaluated in our study.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t003g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t003.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">TGI model</th><th align="left" rowspan="1" colspan="1">Dosage regimen</th><th align="left" rowspan="1" colspan="1">Cell line</th><th align="left" rowspan="1" colspan="1">Literature</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">(1)</td><td align="left" rowspan="1" colspan="1">100mg/kg, weekly for 4 weeks</td><td align="left" rowspan="1" colspan="1">Colon 38</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref071" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(2)</td><td align="left" rowspan="1" colspan="1">50 mg/kg, daily for 4 days</td><td align="left" rowspan="1" colspan="1">Colon 26</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref072" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(3)</td><td align="left" rowspan="1" colspan="1">20 mg/kg, twice a week for 3 weeks</td><td align="left" rowspan="1" colspan="1">HT 29</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref073" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(4)</td><td align="left" rowspan="1" colspan="1">20 mg/kg, three times a week for 3 weeks</td><td align="left" rowspan="1" colspan="1">HT 29</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref074" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(5)</td><td align="left" rowspan="1" colspan="1">5 mg/kg, daily for 9 days</td><td align="left" rowspan="1" colspan="1">SW620</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref075" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(6)</td><td align="left" rowspan="1" colspan="1">20 mg/kg, twice a week for 3 weeks</td><td align="left" rowspan="1" colspan="1">SW620</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref076" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(7)</td><td align="left" rowspan="1" colspan="1">20 mg/kg, every other day for 2 weeks</td><td align="left" rowspan="1" colspan="1">SW620</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref077" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(8)</td><td align="left" rowspan="1" colspan="1">50 mg/kg, every other day for 6 times</td><td align="left" rowspan="1" colspan="1">sensitive LS174T</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref078" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(9)</td><td align="left" rowspan="1" colspan="1">50 mg/kg, every other day for 6 times</td><td align="left" rowspan="1" colspan="1">resistant LS174T</td><td align="left" rowspan="1" colspan="1">[<xref rid="pcbi.1010685.ref078" ref-type="bibr">78</xref>]</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pcbi.1010685.t004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t004</object-id><label>Table 4</label><caption><title>Parameter estimates for the nine TGI models.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t004g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t004.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic toggle="yes">T</italic><sub>d,Tv</sub>, min</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">IC</italic><sub>50</sub>, pmol &#8901; <italic toggle="yes">mg</italic><sup>&#8722;1</sup></th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub>, units</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub>, units</th><th align="left" rowspan="1" colspan="1">&#955;<sub><italic toggle="yes">g</italic></sub> min<sup>&#8722;1</sup></th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic><sub>max</sub>, cm<sup>&#8722;3</sup></th><th align="left" rowspan="1" colspan="1">&#955;<sub>d</sub>, min<sup>&#8722;1</sup></th><th align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1010685.e048">
<alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e048g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e048.jpg"/><mml:math id="M48" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives>
</inline-formula>
</th><th align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1010685.e049">
<alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e049g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e049.jpg"/><mml:math id="M49" display="inline" overflow="scroll"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives>
</inline-formula>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#947;</italic>
<sub>Tv</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Model 1</td><td align="left" rowspan="1" colspan="1">4.9738e2 (4.9736e2,4.9741e2)</td><td align="left" rowspan="1" colspan="1">7.6262e0 (7.5690e0,7.6779e0)</td><td align="left" rowspan="1" colspan="1">6.7387e-1 (6.7368e-1,6.7428e-1)</td><td align="left" rowspan="1" colspan="1">5.1420e0 (5.1326e0,5.1478e0)</td><td align="left" rowspan="1" colspan="1">7.6643e-5 (7.5381e-5,7.7463e-5)</td><td align="left" rowspan="1" colspan="1">4.8414e0 (4.8295e0,4.8492e0)</td><td align="left" rowspan="1" colspan="1">1.1564e-5 (1.0181e-5,1.3015e-5)</td><td align="left" rowspan="1" colspan="1">2.2878e-2 (1.2150e-2,2.7278e-2)</td><td align="left" rowspan="1" colspan="1">3.5396e-2 (1.6802e-2,4.4669e-2)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 2</td><td align="left" rowspan="1" colspan="1">5.8137e2 (5.8136e2,5.8137e2)</td><td align="left" rowspan="1" colspan="1">1.4192e0 (1.4170e0,1.4220e0)</td><td align="left" rowspan="1" colspan="1">2.3961e1 (2.3952e1,2.3973e1)</td><td align="left" rowspan="1" colspan="1">1.6143e2 (1.6141e2,1.6146e2)</td><td align="left" rowspan="1" colspan="1">4.2827e-4 (4.2824e-4,4.2829e-4)</td><td align="left" rowspan="1" colspan="1">1.4204e0 (1.4202e0,1.4204e0)</td><td align="left" rowspan="1" colspan="1">2.7973e-5 (2.7790e-5,2.8156e-5)</td><td align="left" rowspan="1" colspan="1">2.0999e-3 (9.2526e-4,2.5272e-3)</td><td align="left" rowspan="1" colspan="1">1.6150e-1 (1.5918e-1,1.6449e-1)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 3</td><td align="left" rowspan="1" colspan="1">8.9345e2 (8.9342e2,8.9347e2)</td><td align="left" rowspan="1" colspan="1">3.7658e-3 (3.6944e-3,3.8767e-3)</td><td align="left" rowspan="1" colspan="1">1.7511e-1 (1.6683e-1,1.8534e-1)</td><td align="left" rowspan="1" colspan="1">2.3802e-1 (2.3647e-1,2.4322e-1)</td><td align="left" rowspan="1" colspan="1">2.1252e-4 (2.1120e-4,2.1388e-4)</td><td align="left" rowspan="1" colspan="1">1.2468e0 (1.2448e0,1.2502e0)</td><td align="left" rowspan="1" colspan="1">5.0506e-5 (5.0297e-5,5.0895e-5)</td><td align="left" rowspan="1" colspan="1">1.8068e0 (1.8022e0,1.8106e0)</td><td align="left" rowspan="1" colspan="1">5.3202e-3 (3.1314e-3,6.4018e-3)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 4</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">2.5101e-4 (2.4870e-4,2.5343e-4)</td><td align="left" rowspan="1" colspan="1">1.7230e0 (1.6809e0,1.7754e0)</td><td align="left" rowspan="1" colspan="1">4.4318e-5 (3.4239e-5,5.3867e-5)</td><td align="left" rowspan="1" colspan="1">5.2956e-1 (4.3654e-1,5.9777e-1)</td><td align="left" rowspan="1" colspan="1">1.4767e-1 (7.2128e-2,1.8219e-1)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 5</td><td align="left" rowspan="1" colspan="1">1.2537e3 (1.2537e3,1.2537e3)</td><td align="left" rowspan="1" colspan="1">6.9275e-1 (6.9099e-1,6.9642e-1)</td><td align="left" rowspan="1" colspan="1">7.8173e-1 (7.0030e-1,8.4510e-1)</td><td align="left" rowspan="1" colspan="1">5.7608e-1 (5.3271e-1,6.0047e-1)</td><td align="left" rowspan="1" colspan="1">2.2528e-4 (2.2398e-4,2.2612e-4)</td><td align="left" rowspan="1" colspan="1">2.3627e0 (2.3562e0,2.3678e0)</td><td align="left" rowspan="1" colspan="1">3.1695e-6 (2.9728e-6,3.3098e-6)</td><td align="left" rowspan="1" colspan="1">6.2889e-4 (3.7498e-4,7.7701e-4)</td><td align="left" rowspan="1" colspan="1">2.4629e-1 (2.4258e-1,2.5090e-1)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 6</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">2.8371e-4 (2.7986e-4,2.8864e-4)</td><td align="left" rowspan="1" colspan="1">1.1623e1 (1.1504e1,1.1794e1)</td><td align="left" rowspan="1" colspan="1">3.4289e-5 (3.2932e-5,3.6441e-5)</td><td align="left" rowspan="1" colspan="1">1.0461e-2 (2.5496e-3,1.0932e-2)</td><td align="left" rowspan="1" colspan="1">1.5163e0 (1.5001e0,1.5331e0)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 7</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">b</td><td align="left" rowspan="1" colspan="1">1.5008e-4 (1.4464e-4,1.5520e-4)</td><td align="left" rowspan="1" colspan="1">2.6419e0 (2.5477e0,2.7285e0)</td><td align="left" rowspan="1" colspan="1">1.7707e-5 (1.3445e-5,2.0765e-5)</td><td align="left" rowspan="1" colspan="1">7.2275e-1 (7.0288e-1,7.4131e-1)</td><td align="left" rowspan="1" colspan="1">1.0279e-1 (6.6635e-3,2.1899e-1)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 8</td><td align="left" rowspan="1" colspan="1">1.1160e3 (1.1160e3,1.1160e3)</td><td align="left" rowspan="1" colspan="1">8.7883e1 (8.7795e1,8.8040e1)</td><td align="left" rowspan="1" colspan="1">5.0672e-1 (4.6947e-1,5.4911e-1)</td><td align="left" rowspan="1" colspan="1">6.2875e1 (6.2721e1,6.2961e1)</td><td align="left" rowspan="1" colspan="1">2.3163e-4 (2.2959e-4,2.3392e-4)</td><td align="left" rowspan="1" colspan="1">8.9848e0 (8.9516e0,9.0314e0)</td><td align="left" rowspan="1" colspan="1">4.0360e-6 (3.2719e-6,4.6727e-6)</td><td align="left" rowspan="1" colspan="1">1.0464e-2 (6.5112e-3,1.2935e-2)</td><td align="left" rowspan="1" colspan="1">5.0422e-2 (3.6380e-2,6.1261e-2)</td><td align="left" rowspan="1" colspan="1">a</td></tr><tr><td align="left" rowspan="1" colspan="1">Model 9</td><td align="left" rowspan="1" colspan="1">1.3002e3 (1.3002e3,1.3003e3)</td><td align="left" rowspan="1" colspan="1">7.2201e1 (7.2142e1,7.2265e1)</td><td align="left" rowspan="1" colspan="1">1.5250e0 (1.4508e0,1.5971e0)</td><td align="left" rowspan="1" colspan="1">4.9656e1 (4.9637e1,4.9670e1)</td><td align="left" rowspan="1" colspan="1">2.7370e-4 (2.7162e-4,2.7565e-4)</td><td align="left" rowspan="1" colspan="1">7.5644e0 (7.3151e0,7.7718e0)</td><td align="left" rowspan="1" colspan="1">5.5131e-6 (4.8012e-6,5.7914e-6)</td><td align="left" rowspan="1" colspan="1">1.3928e-2 (8.9215e-3,1.6304e-2)</td><td align="left" rowspan="1" colspan="1">8.6216e-1 (8.3173e-1,8.8676e-1)</td><td align="left" rowspan="1" colspan="1">a</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>a: Fixed as 0.2</p></fn><fn id="t004fn002"><p>b: Simulation using parameter estimates obtained from HT29 xenograft tumor under dose regimen (3) (Model 3)</p></fn><fn id="t004fn003"><p>On Table 4, the 0.5 credible interval for each parameter is shown inside the brackets. The numbers of samples used for calculating the empirical mean and associated credible intervals for all the TGI models are 8001, 5101, 10202, 4952, 4801, 7202, 1150, 10501, 9512 respectively.</p></fn></table-wrap-foot></table-wrap><p>The values of parameters shown in <xref rid="pcbi.1010685.t004" ref-type="table">Table 4</xref> also agree with the extent of adverse effects of the studied dosage regimens. Among all the nine models, the estimated value of <italic toggle="yes">IC</italic><sub>50</sub> for model (1) is the largest. It is partially due to more anabolites that are synthesized from a higher level of drug exposure to tumor cells. The DSB-related parameters <italic toggle="yes">E</italic><sub>max</sub>, <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub> of model (2) are the highest, which is caused by the acute accumulation of DNA lesions as a result of daily administration. As for the mild dose schedule featuring models (1) and (3), the amount of single dose plays a more dominant role in determining the levels of <italic toggle="yes">E</italic><sub>max</sub> and <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub>, which is indicated by the larger value of the two model parameters for injection of 100 mg/kg 5-FU than that of 20 mg/kg 5-FU. The values of those growth-related parameters are subject to the characteristics of the cell lines and progression phases of the specific xenograft tumors. Overall, the parameter estimates of 9 xenograft tumor models examined in this study fall in the same order of magnitude. Besides, the computational analysis of 5-FU anabolites-effect relationship(<italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>)) and DSB-effect relationship (<italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>)) are documented in Supporting Information <xref rid="pcbi.1010685.s001" ref-type="supplementary-material">S1 Text</xref>. Fig D&#8212;Fig L in Supporting Information <xref rid="pcbi.1010685.s003" ref-type="supplementary-material">S3 Text</xref> show the histograms for the estimated TGI model parameters. The identifiable and unidentifiable parameters for the TGI models (1)&#8212;(9) are listed on the figure captions in Supporting Information <xref rid="pcbi.1010685.s003" ref-type="supplementary-material">S3 Text</xref>. We conducted a global sensitivity analysis where we first used the Morris method to screen the parameters that have more influence on the model outputs. Then the variance-based global sensitivity analysis, often referred to as Sobol method, is conducted based on the selected parameters. The Morris method revelaed that the changes in the parameters <italic toggle="yes">K</italic><sub><italic toggle="yes">m</italic></sub>, <italic toggle="yes">K</italic><sub><italic toggle="yes">m</italic>,<italic toggle="yes">efflux</italic></sub>, <italic toggle="yes">K</italic><sub><italic toggle="yes">m</italic>,54</sub>, <italic toggle="yes">K</italic><sub><italic toggle="yes">m</italic>,<italic toggle="yes">influx</italic></sub>, <italic toggle="yes">P</italic><sub><italic toggle="yes">max</italic></sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic>,<italic toggle="yes">efflux</italic></sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic>,54</sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic>,75</sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic>,<italic toggle="yes">influx</italic></sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic></sub>, &#955;<sub><italic toggle="yes">d</italic></sub>, &#955;<sub><italic toggle="yes">g</italic></sub>, <italic toggle="yes">k</italic><sub>03</sub>, <italic toggle="yes">k</italic><sub>56</sub>, <italic toggle="yes">k</italic><sub>59</sub>, <italic toggle="yes">k</italic><sub>95</sub>, <italic toggle="yes">k</italic><sub>65</sub> created considerable perturbations on the model output and these were chosen to be analyzed using the Sobol analysis. The detailed discussion of the analysis and the results are provided in Supporting Information <xref rid="pcbi.1010685.s002" ref-type="supplementary-material">S2 Text</xref>. We further used the Sobol global sensitivity to identify the degree of the changes in the model outputs produced by the joint interactions of the input parameters. The first order and total order Sobol index of each parameter with the tumor volume at 5th, 25th and 45 day after treatment begins are given in Supporting Information <xref rid="pcbi.1010685.s002" ref-type="supplementary-material">S2 Text</xref>. The results show that model outputs at 45 th day are more sensitive to &#955;<sub><italic toggle="yes">g</italic></sub>, <italic toggle="yes">P</italic><sub>max</sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic>,<italic toggle="yes">efflux</italic></sub>, and <italic toggle="yes">V</italic><sub><italic toggle="yes">max</italic>,<italic toggle="yes">influx</italic></sub> than the other input factors, which is consistent with the result of preliminary screening by Morris method.</p></sec></sec><sec id="sec015"><title>Quantitative evaluation of treatment efficacy using established TGI models</title><p>We further examined extensively the effect of dosage regimens on cytotoxic effects of 5-FU by looking at the area under the curves of <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) (denoted as <italic toggle="yes">AUC</italic><sub><italic toggle="yes">e</italic>,<italic toggle="yes">a</italic></sub> and <italic toggle="yes">AUC</italic><sub>e,damage</sub> respectively), the area under the time profiles of <italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub> (denoted as <italic toggle="yes">AUC</italic><sub><italic toggle="yes">a</italic></sub> and <italic toggle="yes">AUC</italic><sub><italic toggle="yes">DSB</italic></sub> respectively), the trajectories of <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) (shown in <xref rid="pcbi.1010685.s001" ref-type="supplementary-material">S1 Text</xref>), and tumor responses (<xref rid="pcbi.1010685.g004" ref-type="fig">Fig 4</xref>). The numerical results of <italic toggle="yes">AUC</italic><sub><italic toggle="yes">e</italic>,<italic toggle="yes">a</italic></sub>, <italic toggle="yes">AUC</italic><sub>e,damage</sub>, <italic toggle="yes">AUC</italic><sub><italic toggle="yes">DSB</italic></sub>, and <italic toggle="yes">AUC</italic><sub><italic toggle="yes">a</italic></sub> are shown in <xref rid="pcbi.1010685.t005" ref-type="table">Table 5</xref>. <italic toggle="yes">AUC</italic><sub><italic toggle="yes">e</italic>,<italic toggle="yes">a</italic></sub> and <italic toggle="yes">AUC</italic><sub>e,damage</sub> are used as the indicators of the cumulative cytotoxic effect of the drug and can be used to predict cumulative tumor responses. Following the model design, <italic toggle="yes">AUC</italic><sub>e,damage</sub> increases with the accumulation of drug exposure, while <italic toggle="yes">AUC</italic><sub>e,a</sub> experiences the opposite trend. For the protocols (1), (3), (4), (6), (7), their accumulative doses over a week are similar, so is the accumulative effect of <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>). But by close comparison of the individual <italic toggle="yes">AUC</italic><sub>e,damage</sub>, the DNA damage caused by 100 mg/kg weekly injection exerts more significant anti-tumor effects among those regimens. And the treatment with 20 mg/kg 5-FU every other day (model (7)) stands out with the smallest <italic toggle="yes">AUC</italic><sub>e,a</sub>. Furthermore, through the comparison of the AUC measures calculated for the protocol (2) and protocol (8), we can observe that the moderate dose coupled with the intense dose frequency can lead to striking anti-tumor effects. The <italic toggle="yes">AUC</italic><sub><italic toggle="yes">DSB</italic></sub> and <italic toggle="yes">AUC</italic><sub><italic toggle="yes">a</italic></sub> corresponding to daily 50 mg/kg 5-FU treatment are the extremest in comparison with those of other schemes. Likewise, the associated trajectory of the relative tumor volume change also demonstrates that daily administration of 50 mg/kg 5-FU for 4 times shows more noticeable cytotoxic effects and causes the tumor shrinkage within the first week after the treatment begins. Such phenomenon can be explained by the observation that the intracellular drug action mediators with extensive amounts resulted from frequent injections are present and continue to take effect over a protracted period of time. The simulation results of models (3), (4), (7) and the corresponding calculated <italic toggle="yes">AUC</italic><sub><italic toggle="yes">e</italic></sub> show that given the same size of dose and period of treatment, the more frequent drug injection results in the more eminent drug efficacy. It is also worth looking at the time profiles of <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) for model (1) to assess the combinations of high dose and less frequent schedule. It can be observed that while the drug effects would fade away during the dose intervals, high doses with a weekly schedule can still yield drastic tumor suppression.</p><table-wrap position="float" id="pcbi.1010685.t005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t005</object-id><label>Table 5</label><caption><title>AUC and AUCe for 9 TGI models.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t005g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t005.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="left" rowspan="1" colspan="1">Model 1</th><th align="left" rowspan="1" colspan="1">Model 2</th><th align="left" rowspan="1" colspan="1">Model 3</th><th align="left" rowspan="1" colspan="1">Model 4</th><th align="left" rowspan="1" colspan="1">Model 5</th><th align="left" rowspan="1" colspan="1">Model 6</th><th align="left" rowspan="1" colspan="1">Model 7</th><th align="left" rowspan="1" colspan="1">Model 8</th><th align="left" rowspan="1" colspan="1">Model 9</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1010685.e050">
<alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e050g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e050.jpg"/><mml:math id="M50" display="inline" overflow="scroll"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mspace width="1em"/><mml:mi>a</mml:mi></mml:mrow></mml:msubsup></mml:math></alternatives>
</inline-formula>
</td><td align="char" char="." rowspan="1" colspan="1">4.7900</td><td align="char" char="." rowspan="1" colspan="1">2.3128</td><td align="char" char="." rowspan="1" colspan="1">4.9206</td><td align="char" char="." rowspan="1" colspan="1">3.8823</td><td align="char" char="." rowspan="1" colspan="1">5.0412</td><td align="char" char="." rowspan="1" colspan="1">4.9206</td><td align="char" char="." rowspan="1" colspan="1">3.1336</td><td align="char" char="." rowspan="1" colspan="1">3.9429</td><td align="char" char="." rowspan="1" colspan="1">3.8757</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1010685.e051">
<alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e051g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e051.jpg"/><mml:math id="M51" display="inline" overflow="scroll"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mspace width="2em"/><mml:mi>a</mml:mi></mml:mrow></mml:msubsup></mml:math></alternatives>
</inline-formula>
</td><td align="char" char="." rowspan="1" colspan="1">1.2874</td><td align="char" char="." rowspan="1" colspan="1">33.1088</td><td align="char" char="." rowspan="1" colspan="1">0.3889</td><td align="char" char="." rowspan="1" colspan="1">0.4494</td><td align="char" char="." rowspan="1" colspan="1">1.7674</td><td align="char" char="." rowspan="1" colspan="1">0.3895</td><td align="char" char="." rowspan="1" colspan="1">0.4631</td><td align="char" char="." rowspan="1" colspan="1">0.7832</td><td align="char" char="." rowspan="1" colspan="1">2.4385</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1010685.e052">
<alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e052g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e052.jpg"/><mml:math id="M52" display="inline" overflow="scroll"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mspace width="1em"/><mml:mi>a</mml:mi></mml:mrow></mml:msubsup></mml:math></alternatives>
</inline-formula>
</td><td align="char" char="." rowspan="1" colspan="1">162.4190</td><td align="char" char="." rowspan="1" colspan="1">396.7319</td><td align="char" char="." rowspan="1" colspan="1">17.2567</td><td align="char" char="." rowspan="1" colspan="1">25.8850</td><td align="char" char="." rowspan="1" colspan="1">4.2039</td><td align="char" char="." rowspan="1" colspan="1">17.2567</td><td align="char" char="." rowspan="1" colspan="1">34.5052</td><td align="char" char="." rowspan="1" colspan="1">194.0453</td><td align="char" char="." rowspan="1" colspan="1">194.0453</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1010685.e053">
<alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e053g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e053.jpg"/><mml:math id="M53" display="inline" overflow="scroll"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mspace width="2em"/><mml:mi>a</mml:mi></mml:mrow></mml:msubsup></mml:math></alternatives>
</inline-formula>
</td><td align="char" char="." rowspan="1" colspan="1">2.8343</td><td align="char" char="." rowspan="1" colspan="1">4.0616</td><td align="char" char="." rowspan="1" colspan="1">0.9044</td><td align="char" char="." rowspan="1" colspan="1">1.1920</td><td align="char" char="." rowspan="1" colspan="1">0.6292</td><td align="char" char="." rowspan="1" colspan="1">0.9044</td><td align="char" char="." rowspan="1" colspan="1">1.3578</td><td align="char" char="." rowspan="1" colspan="1">3.6296</td><td align="char" char="." rowspan="1" colspan="1">3.6296</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>a: Calculated by integrating the time courses over a week</p></fn><fn id="t005fn002"><p><italic toggle="yes">AUC</italic><sub><italic toggle="yes">e</italic>,<italic toggle="yes">a</italic></sub> and <italic toggle="yes">AUC</italic><sub>e,damage</sub> are calculated by integration of the profile of <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) over a week respectively. AUC<sub><italic toggle="yes">a</italic></sub> and AUC<sub><italic toggle="yes">DSB</italic></sub>, calculated in the same way as <italic toggle="yes">AUC</italic><sub><italic toggle="yes">e</italic>,<italic toggle="yes">a</italic></sub> and <italic toggle="yes">AUC</italic><sub>e,damage</sub>, are the area under the time profile of normalized count of DSB(<italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic>,<italic toggle="yes">deviation</italic></sub>) and the amount of 5-FU anabolites (<italic toggle="yes">A</italic><sub>5</sub>(<italic toggle="yes">t</italic>)).</p></fn></table-wrap-foot></table-wrap><p>Taken together, 5-FU suppresses cell proliferation of colon cancer in a time- and dose-dependent manner and the accumulative PK exposure can improve the overall therapeutic efficacy. The treatment with daily injection of 50 mg/kg 5-FU four times exhibits the most detrimental effect on tumor burden. A high-dose 5-FU taken over long period may produce significant anti-tumor effects. Regarding the same doses given over the same treatment duration at specific intervals, the more intense schedule may increase the likelihood of exposing vulnerable tumor cells to 5-FU and yields a more significant anti-tumor effect.</p></sec><sec id="sec016"><title>Simulation analysis of tumor resistance towards 5-FU exposure</title><p>In this section, we investigate various scenarios on the mechanisms underlying the resistance of tumor responses towards 5-FU treatment using numerical simulations. We evaluated simultaneous changes in physiologically-related parameters that would generate a resistant behavior. We summarized the parameter variations we used to identify possible resistance mechanisms on <xref rid="pcbi.1010685.t006" ref-type="table">Table 6</xref>, which also lists how these variable changes reflect the biologically relevant resistance mechanisms studied in the literature. The last three entries on the table show our novel hypothesis on other possible causes that might lead to treatment resistance. Considering that resistance may be caused by interwoven cellular pathways, we simulated the simultaneous changes of certain factors to examine the aggregate effects. The Monte Carlo method is applied to generate <italic toggle="yes">N</italic>(= 500) parameter sets and time courses of tumor volume change are simulated for each parameter set. Each parameter set comprises the concerned parameters with newly sampled values from their associated sampling intervals(<xref rid="pcbi.1010685.e054" ref-type="disp-formula">Eq (32)</xref>) and the remaining parameters with baseline values. The resultant time courses are examined for their closeness to the resistant tumor response to identify the parameter changes that resulted in a resistant behavior. The baseline values of parameters are the ones defined for PK and cellular model and the TGI model 8 (sensitive LS174T cell line). The dosage regimen adopted by the model simulations for resistance analysis is the one corresponding to the TGI models (8) and (9). The resistant tumor response is assumed to be the simulation of the TGI model (9). The parameters we experimented on in this section are the ones related with 5-FU drug actions and resistance mechanisms, which are V<sub>max,54</sub>, K<sub>m,54</sub>, G<sub>0</sub>, k<sub>cat</sub>, k<sub>08</sub>, k<sub>59</sub>, k<sub>95</sub>, k<sub>09</sub>, k<sub>5,dNTP</sub>, T<sub><italic toggle="yes">d</italic>,DSB</sub>, <italic toggle="yes">&#945;</italic><sub><italic toggle="yes">TS</italic></sub>, <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic></sub>, <italic toggle="yes">E</italic><sub>max,<italic toggle="yes">damage</italic></sub>, <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub>. The simulation scenarios highlighting their combined effects are: (A) Increased TS expression plus reduced production and stability of TS-FdUMP complex, (B) Accumulation of dUMP plus reduced production and reduced stability of TS-FdUMP complex, (C) Decreased accumulation of anabolites plus reduced production and stability of TS-FdUMP complex, (D) Reduced production and stability of TS-FdUMP complex plus delayed production of DNA fragmentation, (E) Effect of the salvage pathway plus delayed production of DNA fragmentation., (F) The delay of production of damaged cells and the effect of the salvage pathway., (G) The reduced effect of DNA fragmentation on the production of damaged cells plus reduced stability of TS-FdUMP complex. As the effects of specific parameters are analyzed, the values of the others in the model are fixed.
<disp-formula id="pcbi.1010685.e054"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e054g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e054.jpg"/><mml:math id="M54" display="block" overflow="scroll"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mtext>rand</mml:mtext><mml:mo>&#215;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>u</mml:mi></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(32)</label></disp-formula>
Where <inline-formula id="pcbi.1010685.e055"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e055g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e055.jpg"/><mml:math id="M55" display="inline" overflow="scroll"><mml:msubsup><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1010685.e056"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.e056g" position="anchor" orientation="portrait" xlink:href="pcbi.1010685.e056.jpg"/><mml:math id="M56" display="inline" overflow="scroll"><mml:msubsup><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>u</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula> are the lower bound and upper bound of parameter <italic toggle="yes">p</italic><sub><italic toggle="yes">i</italic></sub>. rand represents a random number drawn from the standard uniform distribution. The ranges of variation for each parameter are shown in <xref rid="pcbi.1010685.t006" ref-type="table">Table 6</xref>.</p><table-wrap position="float" id="pcbi.1010685.t006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t006</object-id><label>Table 6</label><caption><title>The range of variation for each parameter and their corresponding biological implication.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t006g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t006.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="4" rowspan="1"><xref rid="pcbi.1010685.t005" ref-type="table">Table 5</xref>: The range of variation for each parameter along with the underlying biological implication</th></tr><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Upper bound</th><th align="left" rowspan="1" colspan="1">Lower bound</th><th align="left" rowspan="1" colspan="1">Biological implication from literature</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">V<sub>max,54</sub></td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">2 fold decrease</td><td align="left" rowspan="1" colspan="1">Decreased accumulation of anabolites [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]; metabolism may predict tumor sensitivity to 5-FU therapy [<xref rid="pcbi.1010685.ref040" ref-type="bibr">40</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub><italic toggle="yes">m</italic>,54</sub>
</td><td align="left" rowspan="1" colspan="1">2 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Decreased accumulation of anabolites</td></tr><tr><td align="left" rowspan="1" colspan="1">G<sub>0</sub></td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">10 fold decrease</td><td align="left" rowspan="1" colspan="1">dUMP accumulation [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">k<sub>cat</sub></td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">10 fold decrease</td><td align="left" rowspan="1" colspan="1">dUMP accumulation</td></tr><tr><td align="left" rowspan="1" colspan="1">k<sub>08</sub></td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">10 fold decrease</td><td align="left" rowspan="1" colspan="1">dUMP accumulation</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">k</italic>
<sub>95,<italic toggle="yes">complex</italic></sub>
</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">10 fold decrease</td><td align="left" rowspan="1" colspan="1">decreased enzyme affinity for FdUMP [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>, <xref rid="pcbi.1010685.ref079" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">k</italic>
<sub>59,<italic toggle="yes">complex</italic></sub>
</td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Decreased stability of ternary complex [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>, <xref rid="pcbi.1010685.ref079" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">k</italic>
<sub>09,<italic toggle="yes">complex</italic></sub>
</td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Decreased stability of ternary complex [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>, <xref rid="pcbi.1010685.ref079" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">k<sub>5,dNTP</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10 fold decrease</td><td align="left" rowspan="1" colspan="1">The effects of salvage pathway on lessoning dNTP pool imbalance [<xref rid="pcbi.1010685.ref080" ref-type="bibr">80</xref>].</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>d,DSB</sub>
</td><td align="left" rowspan="1" colspan="1">2 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Delayed 5-FU-induced DNA fragmentation and cytotoxicity in the resistant cell lines [<xref rid="pcbi.1010685.ref079" ref-type="bibr">79</xref>].</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#945;</italic>
<sub>
<italic toggle="yes">TS</italic>
</sub>
</td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Increased TS protein expression [<xref rid="pcbi.1010685.ref053" ref-type="bibr">53</xref>, <xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>
<italic toggle="yes">d</italic>
</sub>
</td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">The delay of transforming the proliferating cells to damaged cells</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max,<italic toggle="yes">damage</italic></sub>
</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">10 fold decrease</td><td align="left" rowspan="1" colspan="1">The reduced effect of DNA fragmentation on production of damaged cells</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">EC</italic>
<sub>50,<italic toggle="yes">damage</italic></sub>
</td><td align="left" rowspan="1" colspan="1">10 fold increase</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">The reduced effect of DNA fragmentation on production of damaged cells</td></tr></tbody></table></alternatives></table-wrap><p>The departure of each tumor growth time course simulated using a new set of parameters from the time course for resistant LS174T tumor cells (model (9)) is calculated as the sum of the Euclidean distances between the coupled points on the two time course trajectories. The time course closest to the insensitive / resistant tumor response is the one with the smallest departure. The mean time course for a certain case is calculated by averaging all the computed time courses. Maximal and minimal time courses among all the simulation results are determined by calculating the <italic toggle="yes">&#8467;</italic><sub>2</sub>-norm of Euclidean distances between the sample points along certain path and x-axis. <xref rid="pcbi.1010685.t007" ref-type="table">Table 7</xref> demonstrates parameter variations that can give rise to tumor response closest to the resistant LS174T xenograft tumor(model (9)) for all the seven cases A&#8211;G.</p><table-wrap position="float" id="pcbi.1010685.t007" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.t007</object-id><label>Table 7</label><caption><title>Values and fold change from the baseline of the 11 parameters considered in resistance analysis producing the simulations closest to the time course of resistant LS174T xenograft tumor.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pcbi.1010685.t007g" position="float" orientation="portrait" xlink:href="pcbi.1010685.t007.jpg"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Case A</th><th align="left" rowspan="1" colspan="1">Case B</th><th align="left" rowspan="1" colspan="1">Case C</th><th align="left" rowspan="1" colspan="1">Case D</th><th align="left" rowspan="1" colspan="1">Case E</th><th align="left" rowspan="1" colspan="1">Case F</th><th align="left" rowspan="1" colspan="1">Case G</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">V<sub>max,54</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.225e+01(1.2 fold &#8595;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub><italic toggle="yes">m</italic>,54</sub>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.688e+03(1.2 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G<sub>0</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.406e-01(2.2 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">k<sub>cat</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5.417e+01(3.1 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">k<sub>08</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.769e-03(4.7 fold &#8595;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">k</italic>
<sub>95,<italic toggle="yes">complex</italic></sub>
</td><td align="left" rowspan="1" colspan="1">3.434e-02(1.1 fold &#8595;)</td><td align="left" rowspan="1" colspan="1">3.432e-02(1.1 fold &#8595;)</td><td align="left" rowspan="1" colspan="1">1.178e-02(3.3 fold &#8595;)</td><td align="left" rowspan="1" colspan="1">3.289e-02(1.2 fold &#8595;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.410e-02(1.6 fold &#8595;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">k</italic>
<sub>59,<italic toggle="yes">complex</italic></sub>
</td><td align="left" rowspan="1" colspan="1">1.810e+01(6.3 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">6.175e+00(2.1 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">1.853e+01(6.4 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">3.515e+00(1.2 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.119e+00(1.1 fold &#8593;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">k</italic>
<sub>09,<italic toggle="yes">complex</italic></sub>
</td><td align="left" rowspan="1" colspan="1">1.235e+00(8.1 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">1.479e+00(9.7 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">8.614e-01(5.6 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">1.257e+00(8.2 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.342e+00(8.8 fold &#8593;)</td></tr><tr><td align="left" rowspan="1" colspan="1">k<sub>5,dNTP</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.451e+01(9.3 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">2.285e+01(6.2 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T<sub><italic toggle="yes">d</italic>,DSB</sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.104e+01(6.1 fold &#8593;)</td><td align="left" rowspan="1" colspan="1">2.261e+00(1.3 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#945;</italic>
<sub>
<italic toggle="yes">TS</italic>
</sub>
</td><td align="left" rowspan="1" colspan="1">1.037e+01(5.1 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>
<italic toggle="yes">d</italic>
</sub>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.886e+03(2.9 fold &#8593;)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max,<italic toggle="yes">damage</italic></sub>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.461e-01(1.3 fold &#8595;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">EC</italic>
<sub>50,<italic toggle="yes">damage</italic></sub>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.872e+02(9.3 fold &#8593;)</td></tr></tbody></table></alternatives></table-wrap><p>The results that are given in <xref rid="pcbi.1010685.g005" ref-type="fig">Fig 5</xref> demonstrate that the cases (A), (B), (C), (D), (G) achieve the goal of generating the kinetics of tumor volume close to that of TGI model (9). The treatment response of sensitive LS174T xenograft tumor we chose as the baseline level has changed into a resistant response through the coupling of the decreased accumulation of 5FU anabolites and the change in the kinetics of dUMP, TS-FdUMP complex, 5-FU induced DSB, and tumor volume. <xref rid="pcbi.1010685.g005" ref-type="fig">Fig 5C</xref> shows that the decreased net production rate of anabolites accompanied by the reduced stability of TS-FdUMP complex can lead to the mean resistant response even beyond the reference resistant response. For cases (D)and (E) involving the increase in <italic toggle="yes">T</italic><sub><italic toggle="yes">d</italic>,DSB</sub>, the mean time course of 5-FU-induced DSB captures the delaying occurrence of 5-FU induced DSBs and decreased peak values, compared to DSBs induction in the absence of tumor resistance. It can be explained by the depletion of TS-FdUMP complex and strengthened thymidine salvage pathway that reduces the DSB production caused by 5-FU interference, and the salvage pathway with expanded capacity may have more striking effects than decreased FdUMP binding to TS. Among the cases (A), (B), (C), (D) and (G) examining the effect of TS-FdUMP complex related parameters, the highest levels of mean and closest time courses of 5-FU induced DSBs are smaller than the reference level with case (A) and case (C) having the smallest peak values, indicating that the increased TS expression and fewer anabolites may further obstruct the generation of 5-FU induced DSBs. Although the cases (A), (B), (C), (D) and (G) already produce the striking inhibition on DSBs counts, the case (F) leads to the most significant effect by plummeting <italic toggle="yes">N</italic><sub><italic toggle="yes">DSB</italic></sub> to its baseline. The cases (D) and (G) demonstrate similar resistance responses in terms of the tumor volume and magnitude of 5-FU induced DSBs.</p><fig position="float" id="pcbi.1010685.g005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.g005</object-id><label>Fig 5</label><caption><title>The simulation result of resistance analysis.</title><p>The first column is the time profiles of tumor volume; second column, 5-FU anabolites, third column: 5-FU induced DSB. Each row represents each aforementioned scenario. Red dash-dotted line, model simulation of resistant LS174T xenograft tumor; blue solid line: model simulation of sensitive LS174T xenograft tumor; yellow dashed line, the mean time course of 500 computed time courses; &#920;<sub>closest</sub> denotes the parameter set associated with the time course of tumor volume closest to the tumor resistance response; purple dotted line: the time course generated by &#920;<sub>closest</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pcbi.1010685.g005.jpg"/></fig></sec><sec id="sec017"><title>Generalizability of the mechanism-based model</title><p>The generalizability and accuracy of our proposed mechanism-based model on the prediction of tumor responses given a specific dose and dosage regimen are evaluated in this section. We applied different dosing schedules to the TGI model developed above to see how well it can capture the literature data for the target dosing schedules. The values of efficacy-related parameters (i.e. <italic toggle="yes">E</italic><sub>max</sub>, <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub>, <italic toggle="yes">IC</italic><sub>50</sub>, <italic toggle="yes">T</italic><sub>d,Tv</sub>) are kept the same for models (3), (4), (6), (7), because these models have the same amount of single dose, implying that the levels of drug-related intermediates are expected to be the same for the single administration. Because the cell line differences have been addressed through control groups, as shown in <xref rid="pcbi.1010685.t004" ref-type="table">Table 4</xref>, the distinct dose schedules should be the sole drug-regulated factor that drives the differences in the outputs of these models. Therefore, the efficacy-related parameters (i.e. <italic toggle="yes">E</italic><sub>max</sub>, <italic toggle="yes">EC</italic><sub>50,<italic toggle="yes">damage</italic></sub>, <italic toggle="yes">IC</italic><sub>50</sub>, <italic toggle="yes">T</italic><sub>d,Tv</sub>,) of models (4), (6) and (7) are kept equivalent to those of model (3).</p><p>In order to facilitate the assessment of model generalizability, we organized the TGI models except for models (1), (2), (8) and (9) into three different groups according to the rules defined as follows: (A) models with the same type of xenograft tumor and the same single dose but with different frequencies; (B) models with a different type of xenograft tumor under the same protocols; (C) models with a different type of xenograft tumor under the same amount of dose but different frequencies. Models (3) and (4) fall under scenario A. Models (3) and (6) satisfy the condition of scenario B. The last scenario C involves models (3), (4), (6), (7). <xref rid="pcbi.1010685.g004" ref-type="fig">Fig 4D</xref> indicates that the model 4 simulations for protocol (4) given in <xref rid="pcbi.1010685.t003" ref-type="table">Table 3</xref> moderately captures the data, which suggests that the model is structurally stable in the face of changes in the dose frequency. Regarding scenario B, the selections of protocols (3) and (6) from <xref rid="pcbi.1010685.t003" ref-type="table">Table 3</xref> show that the differences in treatment responses are caused by the distinction in the types of xenograft tumor. <xref rid="pcbi.1010685.g004" ref-type="fig">Fig 4C and 4F</xref> show that the model simulations agree well with literature data, indicating that our model can adapt to the different tumor types merely through adjusting the parameters for normal tumor growth. Lastly, the experimental measurements of model (3), (4), (6), and (7) suggest that changing dose schedules and types of cell lines influence tumor responses to multiple doses, which parallels the simulations of these four models. The model outcomes of (3), (6) and (7) successfully capture the experimental dynamics, whereas model (4) has a moderate fit to the experimental data. From the generalizability standpoint, model (4) that shares the same efficacy-related parameters was able to capture the general trend in the observed data. Based on the outcomes of evaluation discussed above, it can be concluded that the proposed model constructed under a certain dosing scheme is capable of predicting the tumor responses towards a similar dosing scheme or the one with the same amount of dose but different administration frequency, as long as the control tumor growth has been captured by the model with no drug input.</p><p>We utilized our models to computationally experiment with dose regimens that are different than the ones given in <xref rid="pcbi.1010685.t003" ref-type="table">Table 3</xref> to further examine the anticancer efficacy of 5-FU treatment. We developed four hypothetical regimens with different combinations of doses, dosing frequencies and treatment durations than the ones we used from the literature. The regimens used for these computational experiments are (A) 100 mg/kg on day 1 of weeks 1 to 6 of an eight-week cycle, for a total of 4 cycles; (B) 50 mg/kg twice a week of weeks 1 to 6 of an eight-week cycle, for a total of 4 cycles; (C) 100 mg/kg on day 1 of weeks 1 to 3 followed by 50 mg/kg twice a week of weeks 4 to 6, for a total of 4 cycles (32 weeks); (D) 50 mg/kg twice a week of weeks 1 to 3 followed by 100 mg/kg on day 1 of weeks 4 to 6, for a total of 4 cycles (32 weeks). The simulation results are shown in <xref rid="pcbi.1010685.g006" ref-type="fig">Fig 6</xref>. Despite having the same total amount of doses over a week, dosage regimens (A) and (B) result in notably different treatment outcomes due to the difference in administration times. The simulation result in <xref rid="pcbi.1010685.g006" ref-type="fig">Fig 6B</xref> shows that within the first cycle, the consecutive twice-a-week injection of 50 mg/kg 5-FU causes a significant tumor shrinkage while the tumor still grows under weekly injection of 100 mg/kg as shown in <xref rid="pcbi.1010685.g006" ref-type="fig">Fig 6A</xref>. <xref rid="pcbi.1010685.g006" ref-type="fig">Fig 6C and 6D</xref> demonstrate that the order of administration of different dosage regimens makes a difference for the treatment options comprising mixed doses. Injection of 50 mg/kg 5-FU twice a week for three weeks following weekly injection of 100 mg/kg 5-FU can inhibit the tumor growth more than the regimen with the opposite order. Computationally, all of the dose regimens presented here show more favorable treatment outcomes compared to the TGI model (1) with the dose regimen 100mg/kg administered weekly for four weeks. Comparison between TGI model(1) and dosing regimen (3) on relative tumor change between three weeks and seven weeks after treatment reveals that shortening the intervals between consecutive lower dosages might yield better outcomes of cytotoxicity. It should be noted that these dose regimens are developed to conduct computational experiments on treatment outcomes and it is necessary to experimentally identify the toxicity profiles and the maximum tolerable doses for the evaluation of dosing schedules before they can be used in a clinical setting. It can be concluded from the computational experiments that applying dosage regimens with high potency after the ones with less potency may result in clinically favorable treatment outcomes.</p><fig position="float" id="pcbi.1010685.g006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1010685.g006</object-id><label>Fig 6</label><caption><title>The simulation results associated with the four novel dosage regimens.</title><p>The regimens under consideration are (A) 100 mg/kg on day 1 of weeks 1 to 6 of a eight-week cycle, for a total of 4 cycles; (B) 50 mg/kg twice a week of weeks 1 to 6 of a eight-week cycle, for a total of 4 cycles; (C) 100 mg/kg on day 1 of weeks 1 to 3 followed by 50 mg/kg twice a week of weeks 4 to 6, for a total of 4 cycles (32 weeks); (D) 50 mg/kg twice a week of weeks 1 to 3 followed by 100 mg/kg on day 1 of weeks 4 to 6, for a total of 4 cycles (32 weeks). Red dash line: model simulation of control; blue solid line: simulation results associated with the four dosage regimens; purple diamond-shaped dot: time of injection of 100 mg/kg 5FU; green round dot: time of injection of 50 mg/kg 5FU.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pcbi.1010685.g006.jpg"/></fig></sec></sec><sec sec-type="conclusions" id="sec018"><title>Discussion</title><p>Mathematical modeling is a powerful tool for capturing the target pharmacology and making predictions on tumor response by translating current understanding towards underlying mechanisms into rigorous mathematical terms. Our physiology-based model allows for the analysis of the dynamics of critical intermediate components related to 5-FU effective drug actions on different time scales and across physical domains. Our cellular model quantitatively reflected the drug effects and related the mechanisms of TS inhibition with disturbance in the dNTP pool and induction of DSBs. The tumor heterogeneity was integrated into the TGI model. The combination of inhibition of proliferating progenitor cells and production of damaged quiescent cells characterized the dynamics of suppressed tumor growth. We converted the time profiles of the 5-FU anabolites and 5-FU-induced DSBs into nonlinear measures of drug effect on inhibiting tumor growth rate and simulating the loss of proliferative cells to provide a realistic prediction of the kinetics of tumor progression under 5-FU treatment. The integrated computational model has the potential to promote the identification of contributions of the physiological intermediates on the clinically favorable responses and potentially enable the precise prediction of medical treatment by antagonistic agents.</p><p>Like the other mathematical models, our model is inevitably influenced by a certain level of uncertainty. The uncertainty may stem from the insufficient measurements, parameter estimation, and alternative model structures, which propagate and aggregate as the model progresses. Furthermore, the solution of the dynamic model could be distracted by a local minimum, in the sense that the model is inherently un-convex. This means that we cannot solely depend on the point estimates provided by the optimization scheme involving the minimization of the objective function. Instead, gaining the knowledge of the joint posterior distribution of model parameters is beneficial in terms of recognizing model identifiability. To that end, we implemented the sampling-based Bayesian inference method through the MCMC technique. The model identifiability was examined by plotting the histograms for each parameter in the sample set. In addition, although the time course measurements for system variables are collected from different literature, we attempt to constrain the scope of data to in vivo or in vitro measurements under 100 mg/kg 5-FU treatment.</p><p>Examination of the combined effect of doses, dosage regimens and duration of treatment via the established model helps us seek the concealed relationship among the treatment protocols. When simulating different dosage regimens, we adapt to the lack of time-series data of fluorinated compounds under other amounts of drug dose than 100 mg/kg by using the cellular model obtained using 100 mg/kg data collections. This may be due to the fact that the 5-FU anabolites possess a rapid rate of transformation, and capturing them under smaller doses to a precise degree may run into technical difficulties. Therefore, it is unrealistic to reevaluate the parameters of the cellular model for each dosing regimen. We used the cellular model determined by fitting to 100mg/kg literature data to simulate all the aforementioned dose and dose schedules. From the model simulations under multiple dosage regimens, we found that a single high dose outperforms the divided dose in terms of drug efficacy of causing tumor shrinkage. Besides, the more intense schedules are able to yield higher therapeutic efficacy compared to the protocols with the same doses and treatment course but less frequent schedules. Taken together, our model can provide an accurate prediction of pharmacological responses to different dosage regimens. Through such investigation, based on our comprehensive model, it has the potential to advance the quantification of chemotherapy potency and to facilitate the development of efficacy optimization.</p><p>We also extended the application of the model to the analysis of tumor resistance responses to the cellular defense mechanisms attributed to tumor insensitivity towards 5-FU, influencing the final treatment outcome. For instance, deoxyuridine triphosphate nucleotidohydrolase (dUTPase), an enzyme catalyzing the degradation of FdUTP to FdUMP, plays a contributory role in enhancing tumor resistance. The experimental study suggests that the cellular (F)dUTP accumulation resulting from dUTPase activity may be related to the insensitivity of tumor to fluoropyrimidine-induced cytotoxicity [<xref rid="pcbi.1010685.ref079" ref-type="bibr">79</xref>]. Moreover, based on the experiments conducted on mice bearing murine mammary carcinoma, the researchers have found that the incorporation into RNA can be blocked by deoxyuridine (dUrd), rescuing the tumor cells from the lethal toxicity of FUra [<xref rid="pcbi.1010685.ref081" ref-type="bibr">81</xref>]. Homologous recombination repair (HR) can protect the tumor cells against exogenous insults. DSBs can be repaired by HR with high fidelity [<xref rid="pcbi.1010685.ref082" ref-type="bibr">82</xref>]. The expression level of the HR proteins is also related to the tumor resistance to the 5-FU anti-tumor effects [<xref rid="pcbi.1010685.ref060" ref-type="bibr">60</xref>]. In addition, it has been proposed that a slow-down in cell cycle and the reduced expression of CDK2 protein can prevent the incorporation of 5-FU metabolites into DNA [<xref rid="pcbi.1010685.ref056" ref-type="bibr">56</xref>]. However, all the cellular mechanisms described are more or less relevant to 5-FU -induced TS inhibition since TS is a key player in cellular nucleotide metabolism. Therefore, we conducted the analysis of tumor resistance responses around 5-FU induced TS inhibition and its downstream events, such as the dNTP pool imbalance and DSB induction. As a result of our computational analysis, the decreased accumulation of 5FU anabolites, variations of dUMP from baseline, reduced production of TS-FdUMP complex, and eased pressure from 5-FU induced DSB may bring about the tumor resistance responses.</p><p>Taken together, our integrated model forms a nested multi-scale structure and quantitatively connects the effects of 5-FU on tumor growth with genome instability and PK-dependent physiological turnover processes, facilitating simulation studies and resistance analysis. The PK, cellular, and tumor growth inhibition models were arranged in accordance with the mechanistic sequence, providing a realistic description of physiological events that ultimately decide the tumor fate. By fitting to literature data measured from preclinical animal models under different dosage regimens, the proposed model showed robust predictive performance and can simulate the PK and PD profiles under different protocols, reflecting that the model has the potential of being applied in the protocol designing phase. Our proposed semi-mechanistic PK/PD approach provides insight towards translation from xenograft tumor study to clinical efficacy analysis in a computational manner. The model simulations can also provide a tool for researchers to compare and evaluate the impacts of various possible dose and dose frequencies on the improvement of drug efficacy, driving the selection of desirable chemotherapy treatment.</p></sec><sec id="sec019" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pcbi.1010685.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Text</label><caption><title>Quantitative analysis of biomeasures <italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>) and <italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>) in TGI model.</title><p>The file details the computational analysis of 5-FU anabolites-effect relationship(<italic toggle="yes">E</italic><sub><italic toggle="yes">a</italic></sub>(<italic toggle="yes">t</italic>)) and DSB-effect relationship (<italic toggle="yes">E</italic><sub><italic toggle="yes">DSB</italic></sub>(<italic toggle="yes">t</italic>)).</p><p>(PDF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1010685.s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pcbi.1010685.s002" position="float" content-type="local-data" orientation="portrait"><label>S2 Text</label><caption><title>Sensitivity analysis.</title><p>(PDF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1010685.s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pcbi.1010685.s003" position="float" content-type="local-data" orientation="portrait"><label>S3 Text</label><caption><title>Identifiability analysis.</title><p>(PDF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pcbi.1010685.s003.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pcbi.1010685.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Butner</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Cristini</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Deisboeck</surname><given-names>TS</given-names></name>. <source>Integrated PK-PD and Agent-Based Modeling in Oncology</source>;<volume>42</volume>(<issue>2</issue>):<fpage>179</fpage>&#8211;<lpage>189</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10928-015-9403-7</pub-id><pub-id pub-id-type="pmid">25588379</pub-id><pub-id pub-id-type="pmcid">PMC4985529</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref002"><label>2</label><mixed-citation publication-type="book"><name name-style="western"><surname>Talevi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bellera</surname><given-names>CL</given-names></name>. <part-title>One-Compartment Pharmacokinetic Model</part-title>. In: <part-title>The ADME Encyclopedia: A Comprehensive Guide on Biopharmacy and Pharmacokinetics</part-title>. <publisher-name>Springer International Publishing</publisher-name>;. p. <fpage>1</fpage>&#8211;<lpage>8</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/978-3-030-51519-5_58-1</pub-id>.</mixed-citation></ref><ref id="pcbi.1010685.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gallo</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Vicini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Orlansky</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <etal>et al</etal>. <source>Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors</source>;<volume>10</volume>(<issue>23</issue>):<fpage>8048</fpage>&#8211;<lpage>8058</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0822</pub-id><pub-id pub-id-type="pmid">15585640</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>. <source>Pharmacokinetic-Pharmacodynamic Modeling and Simulation</source>;<volume>71</volume>(<issue>1</issue>):<fpage>18</fpage>. 27245426</mixed-citation></ref><ref id="pcbi.1010685.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lovejoy</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Shafer</surname><given-names>SL</given-names></name>. <source>Comparison of Some Control Strategies for Three-Compartment PK/PD Models</source>;<volume>22</volume>(<issue>6</issue>):<fpage>525</fpage>&#8211;<lpage>550</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF02353793</pub-id><pub-id pub-id-type="pmid">7473080</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cort&#237;nez</surname><given-names>LI</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name>. <source>Modeling the Pharmacokinetics and Pharmacodynamics of Sevoflurane Using Compartment Models in Children and Adults</source>;<volume>28</volume>(<issue>10</issue>):<fpage>834</fpage>&#8211;<lpage>840</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/pan.13465</pub-id><pub-id pub-id-type="pmid">30117213</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nielsen</surname><given-names>EI</given-names></name>, <name name-style="western"><surname>Cars</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name>. <source>Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: A Step toward Model-Based Dose Optimization</source>;<volume>55</volume>(<issue>10</issue>):<fpage>4619</fpage>&#8211;<lpage>4630</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.00182-11</pub-id><pub-id pub-id-type="pmid">21807983</pub-id><pub-id pub-id-type="pmcid">PMC3186970</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Daryani</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Tagen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Carcaboso</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <source>Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma</source>;<volume>5</volume>(<issue>4</issue>):<fpage>211</fpage>&#8211;<lpage>221</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/psp4.12075</pub-id><pub-id pub-id-type="pmid">27104090</pub-id><pub-id pub-id-type="pmcid">PMC4834132</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Moes</surname><given-names>DJAR</given-names></name>, <name name-style="western"><surname>van Hasselt</surname><given-names>JGC</given-names></name>, <name name-style="western"><surname>Swen</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Guchelaar</surname><given-names>H</given-names></name>. <source>A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors</source>;<volume>8</volume>(<issue>10</issue>):<fpage>720</fpage>&#8211;<lpage>737</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/psp4.12450</pub-id><pub-id pub-id-type="pmid">31250989</pub-id><pub-id pub-id-type="pmcid">PMC6813171</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Murphy</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jaafari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dobrovolny</surname><given-names>HM</given-names></name>. <source>Differences in Predictions of ODE Models of Tumor Growth: A Cautionary Example</source>;<volume>16</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12885-016-2164-x</pub-id><pub-id pub-id-type="pmid">26921070</pub-id><pub-id pub-id-type="pmcid">PMC4768423</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soto</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Staab</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Doege</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Freiwald</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Munzert</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Troc&#243;niz</surname><given-names>IF</given-names></name>. <source>Comparison of Different Semi-Mechanistic Models for Chemotherapy-Related Neutropenia: Application to BI 2536 a Plk-1 Inhibitor</source>;<volume>68</volume>(<issue>6</issue>):<fpage>1517</fpage>&#8211;<lpage>1527</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00280-011-1647-3</pub-id><pub-id pub-id-type="pmid">21516508</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tuntland</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ethell</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kosaka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Blasco</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zang</surname><given-names>RX</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>M</given-names></name>, <etal>et al</etal>. <source>Implementation of Pharmacokinetic and Pharmacodynamic Strategies in Early Research Phases of Drug Discovery and Development at Novartis Institute of Biomedical Research</source>;<volume>5</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphar.2014.00174</pub-id><pub-id pub-id-type="pmid">25120485</pub-id><pub-id pub-id-type="pmcid">PMC4112793</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Felmlee</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Mager</surname><given-names>DE</given-names></name>. <source>Mechanism-Based Pharmacodynamic Modeling</source>;<volume>929</volume>:<fpage>583</fpage>&#8211;<lpage>600</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/978-1-62703-050-2_21</pub-id><pub-id pub-id-type="pmid">23007443</pub-id><pub-id pub-id-type="pmcid">PMC3684160</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wright</surname><given-names>DFB</given-names></name>, <name name-style="western"><surname>Winter</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Duffull</surname><given-names>SB</given-names></name>. <source>Understanding the Time Course of Pharmacological Effect: A PKPD Approach</source>;<volume>71</volume>(<issue>6</issue>):<fpage>815</fpage>&#8211;<lpage>823</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03925.x</pub-id><pub-id pub-id-type="pmid">21272054</pub-id><pub-id pub-id-type="pmcid">PMC3099368</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name>. <source>Moving from Basic towards Systems Pharmacodynamic Models</source>;<volume>102</volume>(<issue>9</issue>):<fpage>2930</fpage>&#8211;<lpage>2940</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jps.23590</pub-id><pub-id pub-id-type="pmid">23681608</pub-id><pub-id pub-id-type="pmcid">PMC3743951</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gibbs</surname><given-names>JP</given-names></name>. <source>Prediction of Exposure&#8211;Response Relationships to Support First-in-Human Study Design</source>;<volume>12</volume>(<issue>4</issue>):<fpage>750</fpage>&#8211;<lpage>758</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1208/s12248-010-9236-7</pub-id><pub-id pub-id-type="pmid">20967521</pub-id><pub-id pub-id-type="pmcid">PMC2976982</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>YN</given-names></name>, <name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name>. <source>Transit Compartments versus Gamma Distribution Function to Model Signal Transduction Processes in Pharmacodynamics</source>;<volume>87</volume>(<issue>6</issue>):<fpage>732</fpage>&#8211;<lpage>737</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/js970414z</pub-id><pub-id pub-id-type="pmid">9607951</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mager</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name>. <source>Pharmacodynamic Modeling of Time-Dependent Transduction Systems</source>;<volume>70</volume>(<issue>3</issue>):<fpage>210</fpage>&#8211;<lpage>216</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1067/mcp.2001.118244</pub-id><pub-id pub-id-type="pmid">11557908</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Ebling</surname><given-names>WF</given-names></name>. <source>Convergence of Direct and Indirect Pharmacodynamic Response Models</source>;<volume>23</volume>(<issue>1</issue>):<fpage>5</fpage>&#8211;<lpage>8</lpage>; discussion 9&#8211;10. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF02353781</pub-id><pub-id pub-id-type="pmid">8576844</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kobuchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Okada</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Imoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kuwano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Takada</surname><given-names>K</given-names></name>. <source>Pharmacokinetic/Pharmacodynamic Modeling of 5-Fluorouracil by Using a Biomarker to Predict Tumor Growth in a Rat Model of Colorectal Cancer</source>;<volume>102</volume>(<issue>6</issue>):<fpage>2056</fpage>&#8211;<lpage>2067</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jps.23547</pub-id><pub-id pub-id-type="pmid">23592368</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kobuchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name>. <source>Application of Pharmacometrics of 5-Fluorouracil to Personalized Medicine: A Tool for Predicting Pharmacokinetic-Pharmacodynamic/Toxicodynamic Responses</source>;<volume>40</volume>(<issue>12</issue>):<fpage>6585</fpage>&#8211;<lpage>6597</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.21873/anticanres.14683</pub-id><pub-id pub-id-type="pmid">33288553</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Simeoni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Magni</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cammia</surname><given-names>C</given-names></name>, <name name-style="western"><surname>De Nicolao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Croci</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Pesenti</surname><given-names>E</given-names></name>, <etal>et al</etal>. <source>Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents</source>;<volume>64</volume>(<issue>3</issue>):<fpage>1094</fpage>&#8211;<lpage>1101</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2524</pub-id><pub-id pub-id-type="pmid">14871843</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Arshad</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Ploylearmsaeng</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Doroshyenko</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Langer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sch&#246;mig</surname><given-names>E</given-names></name>, <etal>et al</etal>. <source>Prediction of Exposure-Driven Myelotoxicity of Continuous Infusion 5-Fluorouracil by a Semi-Physiological Pharmacokinetic-Pharmacodynamic Model in Gastrointestinal Cancer Patients</source>;<volume>85</volume>(<issue>4</issue>):<fpage>711</fpage>&#8211;<lpage>722</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00280-019-04028-5</pub-id><pub-id pub-id-type="pmid">32152679</pub-id><pub-id pub-id-type="pmcid">PMC7125253</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sakai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kobuchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sakaeda</surname><given-names>T</given-names></name>. <source>A Physiologically Based Pharmacokinetic-Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules</source>;<volume>46</volume>(<issue>2</issue>):<fpage>301</fpage>&#8211;<lpage>315</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s13318-021-00674-4</pub-id><pub-id pub-id-type="pmid">33606175</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tate</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ajamie</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Beckmann</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>EM</given-names></name>, <etal>et al</etal>. <source>Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts</source>;<volume>20</volume>(<issue>14</issue>):<fpage>3763</fpage>&#8211;<lpage>3774</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2846</pub-id><pub-id pub-id-type="pmid">24850847</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Altinok</surname><given-names>A</given-names></name>, <name name-style="western"><surname>L&#233;vi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Goldbeter</surname><given-names>A</given-names></name>. <source>Identifying Mechanisms of Chronotolerance and Chronoefficacy for the Anticancer Drugs 5-Fluorouracil and Oxaliplatin by Computational Modeling</source>;<volume>36</volume>(<issue>1</issue>):<fpage>20</fpage>&#8211;<lpage>38</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejps.2008.10.024</pub-id><pub-id pub-id-type="pmid">19041394</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kubota</surname><given-names>T</given-names></name>. <source>5-Fluorouracil and Dihydropyrimidine Dehydrogenase</source>;<volume>8</volume>(<issue>3</issue>):<fpage>127</fpage>&#8211;<lpage>131</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10147-003-0319-7</pub-id><pub-id pub-id-type="pmid">12851835</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Miura</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kinouchi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ishida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fujibuchi</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Naitoh</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name>, <etal>et al</etal>. <source>5-Fu Metabolism in Cancer and Orally-Administrable 5-Fu Drugs</source>;<volume>2</volume>(<issue>3</issue>):<fpage>1717</fpage>&#8211;<lpage>1730</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cancers2031717</pub-id><pub-id pub-id-type="pmid">24281184</pub-id><pub-id pub-id-type="pmcid">PMC3837334</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>van Groeningen</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Laurensse</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>. <source>A Comparison of 5-Fluorouracil Metabolism in Human Colorectal Cancer and Colon Mucosa</source>;<volume>68</volume>(<issue>9</issue>):<fpage>1903</fpage>&#8211;<lpage>1909</lpage>. <pub-id pub-id-type="pmid">1717130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19911101)68:9&lt;1903::aid-cncr2820680910&gt;3.0.co;2-9</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Longley</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Harkin</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>PG</given-names></name>. <source>5-Fluorouracil: Mechanisms of Action and Clinical Strategies</source>;<volume>3</volume>(<issue>5</issue>):<fpage>330</fpage>&#8211;<lpage>338</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrc1074</pub-id><pub-id pub-id-type="pmid">12724731</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>van der Wilt</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>van Groeningen</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Smid</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Meijer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>. <source>Thymidylate Synthase Inhibition after Administration of Fluorouracil with or without Leucovorin in Colon Cancer Patients: Implications for Treatment with Fluorouracil</source>;<volume>12</volume>(<issue>10</issue>):<fpage>2035</fpage>&#8211;<lpage>2042</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1200/JCO.1994.12.10.2035</pub-id><pub-id pub-id-type="pmid">7931471</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Van Triest</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Giaccone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>. <source>Downstream Molecular Determinants of Response to 5-Fluorouracil and Antifolate Thymidylate Synthase Inhibitors</source>;<volume>11</volume>(<issue>4</issue>):<fpage>385</fpage>&#8211;<lpage>391</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1023/a:1008351221345</pub-id><pub-id pub-id-type="pmid">10847455</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Triest</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>van Hensbergen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Smid</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Telleman</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schoenmakers</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <source>Thymidylate Synthase Level as the Main Predictive Parameter for Sensitivity to 5-Fluorouracil, but Not for Folate-Based Thymidylate Synthase Inhibitors, in 13 Nonselected Colon Cancer Cell Lines</source>;<volume>5</volume>(<issue>3</issue>):<fpage>643</fpage>&#8211;<lpage>654</lpage>. <pub-id pub-id-type="pmid">10100718</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kohnken</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kodigepalli</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>L</given-names></name>. <source>Regulation of Deoxynucleotide Metabolism in Cancer: Novel Mechanisms and Therapeutic Implications</source>;<volume>14</volume>:<fpage>176</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12943-015-0446-6</pub-id><pub-id pub-id-type="pmid">26416562</pub-id><pub-id pub-id-type="pmcid">PMC4587406</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ser</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mehrmohamadi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <etal>et al</etal>. <source>Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow</source>;<volume>15</volume>(<issue>11</issue>):<fpage>2367</fpage>&#8211;<lpage>2376</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.035</pub-id><pub-id pub-id-type="pmid">27264180</pub-id><pub-id pub-id-type="pmcid">PMC4909568</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wyatt</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>DM</given-names></name>. <source>Participation of DNA Repair in the Response to 5-Fluorouracil</source>;<volume>66</volume>(<issue>5</issue>):<fpage>788</fpage>&#8211;<lpage>799</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00018-008-8557-5</pub-id><pub-id pub-id-type="pmid">18979208</pub-id><pub-id pub-id-type="pmcid">PMC2649968</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yoshioka</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hiraoka</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Koyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hirota</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ayusawa</surname><given-names>D</given-names></name>, <etal>et al</etal>. <source>Deoxyribonucleoside Triphosphate Imbalance. 5-Fluorodeoxyuridine-induced DNA Double Strand Breaks in Mouse FM3A Cells and the Mechanism of Cell Death</source>;<volume>262</volume>(<issue>17</issue>):<fpage>8235</fpage>&#8211;<lpage>8241</lpage>. <pub-id pub-id-type="pmid">2954951</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Valdiglesias</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Giunta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fenech</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Neri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bonassi</surname><given-names>S</given-names></name>. <source><italic toggle="yes">&#947;</italic>H2AX as a Marker of DNA Double Strand Breaks and Genomic Instability in Human Population Studies</source>. <year>2013</year><month>Jul-Sep</month>;<volume>753</volume>(<issue>1</issue>):<fpage>24</fpage>&#8211;<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.mrrev.2013.02.001</pub-id><pub-id pub-id-type="pmid">23416207</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Saleh</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>El-Awady</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Anis</surname><given-names>N</given-names></name>. <source>Predictive Markers for the Response to 5-Fluorouracil Therapy in Cancer Cells: Constant-field Gel Electrophoresis as a Tool for Prediction of Response to 5-Fluorouracil-Based Chemotherapy</source>;<volume>5</volume>(<issue>1</issue>):<fpage>321</fpage>&#8211;<lpage>327</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/ol.2012.965</pub-id><pub-id pub-id-type="pmid">23255942</pub-id><pub-id pub-id-type="pmcid">PMC3525493</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wolf</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Presant</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Servis</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>el Tahtawy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Albright</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>PB</given-names></name>, <etal>et al</etal>. <source>Tumor Trapping of 5-Fluorouracil: In Vivo 19F NMR Spectroscopic Pharmacokinetics in Tumor-Bearing Humans and Rabbits</source>;<volume>87</volume>(<issue>1</issue>):<fpage>492</fpage>&#8211;<lpage>496</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.87.1.492</pub-id><pub-id pub-id-type="pmid">2296605</pub-id><pub-id pub-id-type="pmcid">PMC53290</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maring</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>van Kuilenburg</surname><given-names>ABP</given-names></name>, <name name-style="western"><surname>Haasjes</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Piersma</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Groen</surname><given-names>HJM</given-names></name>, <name name-style="western"><surname>Uges</surname><given-names>DRA</given-names></name>, <etal>et al</etal>. <source>Reduced 5-FU Clearance in a Patient with Low DPD Activity Due to Heterozygosity for a Mutant Allele of the DPYD Gene</source>;<volume>86</volume>(<issue>7</issue>):<fpage>1028</fpage>&#8211;<lpage>1033</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6600208</pub-id><pub-id pub-id-type="pmid">11953843</pub-id><pub-id pub-id-type="pmcid">PMC2364178</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Kuilenburg</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Maring</surname><given-names>JG</given-names></name>. <source>Evaluation of 5-Fluorouracil Pharmacokinetic Models and Therapeutic Drug Monitoring in Cancer Patients</source>;<volume>14</volume>(<issue>7</issue>):<fpage>799</fpage>&#8211;<lpage>811</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2217/pgs.13.54</pub-id><pub-id pub-id-type="pmid">23651027</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Higashimori</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yamaoka</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>T</given-names></name>. <source>Dose-Dependency in Local Disposition of 5-Fluorouracil under Non-Steady-State Condition in Rat Liver</source>;<volume>89</volume>(<issue>1</issue>):<fpage>100</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="pmid">10664542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200001)89:1&lt;100::AID-JPS10&gt;3.0.CO;2-L</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wolf</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Waluch</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Presant</surname><given-names>CA</given-names></name>. <source>Non-Invasive 19F-NMRS of 5-Fluorouracil in Pharmacokinetics and Pharmacodynamic Studies</source>;<volume>11</volume>(<issue>7</issue>):<fpage>380</fpage>&#8211;<lpage>387</lpage>. <pub-id pub-id-type="pmid">9859944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1099-1492(1998110)11:7&lt;380::aid-nbm517&gt;3.0.co;2-q</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bading</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Yoo</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Fissekis</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Alauddin</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>D&#8217;Argenio</surname><given-names>DZ</given-names></name>, <name name-style="western"><surname>Conti</surname><given-names>PS</given-names></name>. <source>Kinetic Modeling of 5-Fluorouracil Anabolism in Colorectal Adenocarcinoma: A Positron Emission Tomography Study in Rats</source>;<volume>63</volume>(<issue>13</issue>):<fpage>3667</fpage>&#8211;<lpage>3674</lpage>. <pub-id pub-id-type="pmid">12839957</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Aboagye</surname><given-names>EO</given-names></name>, <name name-style="western"><surname>Saleem</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Osman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>PM</given-names></name>. <source>Extraction of 5-Fluorouracil by Tumor and Liver: A Noninvasive Positron Emission Tomography Study of Patients with Gastrointestinal Cancer</source>;<volume>61</volume>(<issue>13</issue>):<fpage>4937</fpage>&#8211;<lpage>4941</lpage>. <pub-id pub-id-type="pmid">11431319</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nishino</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matsuoka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kamoshida</surname><given-names>S</given-names></name>. <source>Immunohistochemical Analysis of Organic Anion Transporter 2 and Reduced Folate Carrier 1 in Colorectal Cancer: Significance as a Predictor of Response to Oral Uracil/Ftorafur plus Leucovorin Chemotherapy</source>;<volume>1</volume>(<issue>4</issue>):<fpage>661</fpage>&#8211;<lpage>667</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/mco.2013.104</pub-id><pub-id pub-id-type="pmid">24649225</pub-id><pub-id pub-id-type="pmcid">PMC3916200</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bading</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Alauddin</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Fissekis</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Shahinian</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Joung</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Spector</surname><given-names>T</given-names></name>, <etal>et al</etal>. <source>Blocking Catabolism with Eniluracil Enhances PET Studies of 5-[18F]Fluorouracil Pharmacokinetics</source>;<volume>41</volume>(<issue>10</issue>):<fpage>1714</fpage>&#8211;<lpage>1724</lpage>. <pub-id pub-id-type="pmid">11038003</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shen</surname><given-names>Yq</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Xb</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>Yr</given-names></name>, <name name-style="western"><surname>Ning</surname><given-names>Xj</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>Xj</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>Bx</given-names></name>, <etal>et al</etal>. <source>The Effects of Storage Time of Colorectal Cancer Tissue on the Detection of K-ras Gene</source>;<volume>42</volume>(<issue>8</issue>):<fpage>478</fpage>&#8211;<lpage>481</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1309/LM030FHMRRUWKQWH</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Roberts</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Hyatt</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Honts</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Changchien</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Maley</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Maley</surname><given-names>F</given-names></name>, <etal>et al</etal>. <source>Structure of the Y94F Mutant of Escherichia Coli Thymidylate Synthase</source>;<volume>62</volume>:<fpage>840</fpage>&#8211;<lpage>843</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S1744309106029691</pub-id><pub-id pub-id-type="pmid">16946460</pub-id><pub-id pub-id-type="pmcid">PMC2242863</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Morrison</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Allegra</surname><given-names>CJ</given-names></name>. <source>Folate Cycle Kinetics in Human Breast Cancer Cells</source>;<volume>264</volume>(<issue>18</issue>):<fpage>10552</fpage>&#8211;<lpage>10566</lpage>. <pub-id pub-id-type="pmid">2732237</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref052"><label>52</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Moore</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dunlap</surname><given-names>RB</given-names></name>. <source>Evidence for the Existence of Covalent Nucleotide-Thymidylate Synthase Complexes, Identification of Site of Attachment, and Enhancement by Folates</source>;<volume>261</volume>(<issue>27</issue>):<fpage>12745</fpage>&#8211;<lpage>12749</lpage>. <pub-id pub-id-type="pmid">3745210</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref053"><label>53</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Parr</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Drake</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Gress</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Steinberg</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Allegra</surname><given-names>CJ</given-names></name>. <source>5-Fluorouracil-Mediated Thymidylate Synthase Induction in Malignant and Nonmalignant Human Cells</source>;<volume>56</volume>(<issue>2</issue>):<fpage>231</fpage>&#8211;<lpage>235</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0006-2952(98)00152-x</pub-id><pub-id pub-id-type="pmid">9698077</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref054"><label>54</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Washtien</surname><given-names>WL</given-names></name>. <source>Increased Levels of Thymidylate Synthetase in Cells Exposed to 5-Fluorouracil</source>;<volume>25</volume>(<issue>1</issue>):<fpage>171</fpage>&#8211;<lpage>177</lpage>. <pub-id pub-id-type="pmid">6708932</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref055"><label>55</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>van Triest</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Backus</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Kuiper</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>van der Wilt</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>. <source>Molecular Downstream Events and Induction of Thymidylate Synthase in Mutant and Wild-Type P53 Colon Cancer Cell Lines after Treatment with 5-Fluorouracil and the Thymidylate Synthase Inhibitor Raltitrexed</source>;<volume>36</volume>(<issue>7</issue>):<fpage>916</fpage>&#8211;<lpage>924</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0959-8049(00)00026-5</pub-id><pub-id pub-id-type="pmid">10785598</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref056"><label>56</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Backus</surname><given-names>HHJ</given-names></name>, <name name-style="western"><surname>Freemantle</surname><given-names>S</given-names></name>, <name name-style="western"><surname>van Triest</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Codacci-Pisanelli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>van der Wilt</surname><given-names>CL</given-names></name>, <etal>et al</etal>. <source>Induction of Thymidylate Synthase as a 5-Fluorouracil Resistance Mechanism</source>;<volume>1587</volume>(<issue>2-3</issue>):<fpage>194</fpage>&#8211;<lpage>205</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0925-4439(02)00082-0</pub-id><pub-id pub-id-type="pmid">12084461</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref057"><label>57</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Berne</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Gustavsson</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Almersj&#246;</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Spears</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Fr&#246;sing</surname><given-names>R</given-names></name>. <source>Sequential Methotrexate/5-FU: FdUMP Formation and TS Inhibition in a Transplantable Rodent Colon Adenocarcinoma</source>;<volume>16</volume>(<issue>3</issue>):<fpage>237</fpage>&#8211;<lpage>242</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF00293984</pub-id><pub-id pub-id-type="pmid">3698165</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref058"><label>58</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Setzer</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mole</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Copeland</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Rogers</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kavlock</surname><given-names>RJ</given-names></name>. <source>Toward a Biologically Based Dose-Response Model for Developmental Toxicity of 5-Fluorouracil in the Rat: A Mathematical Construct</source>;<volume>59</volume>(<issue>1</issue>):<fpage>49</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="pmid">11134543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/59.1.49</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref059"><label>59</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Noordhuis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Holwerda</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Van der Wilt</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Van Groeningen</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Smid</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Meijer</surname><given-names>S</given-names></name>, <etal>et al</etal>. <source>5-Fluorouracil Incorporation into RNA and DNA in Relation to Thymidylate Synthase Inhibition of Human Colorectal Cancers</source>;<volume>15</volume>(<issue>7</issue>):<fpage>1025</fpage>&#8211;<lpage>1032</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/annonc/mdh264</pub-id><pub-id pub-id-type="pmid">15205195</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref060"><label>60</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Srinivas</surname><given-names>US</given-names></name>, <name name-style="western"><surname>Dyczkowski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bei&#223;barth</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gaedcke</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mansour</surname><given-names>WY</given-names></name>, <name name-style="western"><surname>Borgmann</surname><given-names>K</given-names></name>, <etal>et al</etal>. <source>5-Fluorouracil Sensitizes Colorectal Tumor Cells towards Double Stranded DNA Breaks by Interfering with Homologous Recombination Repair</source>;<volume>6</volume>(<issue>14</issue>):<fpage>12574</fpage>&#8211;<lpage>12586</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.3728</pub-id><pub-id pub-id-type="pmid">25909291</pub-id><pub-id pub-id-type="pmcid">PMC4494959</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref061"><label>61</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Falzacappa</surname><given-names>MVV</given-names></name>, <name name-style="western"><surname>Ronchini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Faretta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Iacobucci</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Di Ror&#224;</surname><given-names>AGL</given-names></name>, <name name-style="western"><surname>Martinelli</surname><given-names>G</given-names></name>, <etal>et al</etal>. <source>The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias</source>;<volume>14</volume>(<issue>4</issue>):<fpage>889</fpage>&#8211;<lpage>898</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0276</pub-id><pub-id pub-id-type="pmid">25667168</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref062"><label>62</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Koch</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Krzyzanski</surname><given-names>W</given-names></name>, <name name-style="western"><surname>P&#233;rez-Ruixo</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Schropp</surname><given-names>J</given-names></name>. <source>Modeling of Delays in PKPD: Classical Approaches and a Tutorial for Delay Differential Equations</source>;<volume>41</volume>(<issue>4</issue>):<fpage>291</fpage>&#8211;<lpage>318</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10928-014-9368-y</pub-id><pub-id pub-id-type="pmid">25142056</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref063"><label>63</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Krzyzanski</surname><given-names>W</given-names></name>. <source>Interpretation of Transit Compartments Pharmacodynamic Models as Lifespan Based Indirect Response Models</source>;<volume>38</volume>(<issue>2</issue>):<fpage>179</fpage>&#8211;<lpage>204</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10928-010-9183-z</pub-id><pub-id pub-id-type="pmid">21107661</pub-id><pub-id pub-id-type="pmcid">PMC3177953</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref064"><label>64</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vihola</surname><given-names>M</given-names></name>. <source>Robust Adaptive Metropolis Algorithm with Coerced Acceptance Rate</source>;<volume>22</volume>(<issue>5</issue>):<fpage>997</fpage>&#8211;<lpage>1008</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11222-011-9269-5</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref065"><label>65</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Adams</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Leffert</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Craig</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Spector</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pizzorno</surname><given-names>G</given-names></name>. <source>In Vivo Effect of 5-Ethynyluracil on 5-Fluorouracil Metabolism Determined by 19F Nuclear Magnetic Resonance Spectroscopy</source>;<volume>59</volume>(<issue>1</issue>):<fpage>122</fpage>&#8211;<lpage>127</lpage>. <pub-id pub-id-type="pmid">9892196</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref066"><label>66</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kamm</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Rietjens</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Vervoort</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Heerschap</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rosenbusch</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hofs</surname><given-names>HP</given-names></name>, <etal>et al</etal>. <source>Effect of Modulators on 5-Fluorouracil Metabolite Patterns in Murine Colon Carcinoma Determined by in Vitro 19F Nuclear Magnetic Resonance Spectroscopy</source>;<volume>54</volume>(<issue>16</issue>):<fpage>4321</fpage>&#8211;<lpage>4326</lpage>. <pub-id pub-id-type="pmid">8044779</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref067"><label>67</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Laar</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>van der Wilt</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Rustum</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Noordhuis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Smid</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>, <etal>et al</etal>. <source>Therapeutic Efficacy of Fluoropyrimidines Depends on the Duration of Thymidylate Synthase Inhibition in the Murine Colon 26-B Carcinoma Tumor Model</source>;<volume>2</volume>(<issue>8</issue>):<fpage>1327</fpage>&#8211;<lpage>1333</lpage>. <pub-id pub-id-type="pmid">9816304</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref068"><label>68</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Noordhuis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Holwerda</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Van Laar</surname><given-names>JaM</given-names></name>, <name name-style="western"><surname>Van der Wilt</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>. <source>A Non-Radioactive Sensitive Assay to Measure 5-Fluorouracil Incorporation into DNA of Solid Tumors</source>;<volume>23</volume>(<issue>8-9</issue>):<fpage>1481</fpage>&#8211;<lpage>1484</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1081/NCN-200027699</pub-id><pub-id pub-id-type="pmid">15571281</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref069"><label>69</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Spears</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Shahinian</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Moran</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Heidelberger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Corbett</surname><given-names>TH</given-names></name>. <source>In Vivo Kinetics of Thymidylate Synthetase Inhibition of 5-Fluorouracil-Sensitive and -Resistant Murine Colon Adenocarcinomas</source>;<volume>42</volume>(<issue>2</issue>):<fpage>450</fpage>&#8211;<lpage>456</lpage>. <pub-id pub-id-type="pmid">6173112</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref070"><label>70</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tattersall</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Harrap</surname><given-names>KR</given-names></name>. <source>Changes in the Deoxyribonucleoside Triphosphate Pools of Mouse 5178Y Lymphoma Cells Following Exposure to Methotrexate or 5-Fluorouracil</source>;<volume>33</volume>(<issue>12</issue>):<fpage>3086</fpage>&#8211;<lpage>3090</lpage>. <pub-id pub-id-type="pmid">4543390</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref071"><label>71</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nadal</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>van Groeningen</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name>. <source>Schedule-Dependency of in Vivo Modulation of 5-Fluorouracil by Leucovorin and Uridine in Murine Colon Carcinoma</source>;<volume>7</volume>(<issue>2-3</issue>):<fpage>163</fpage>&#8211;<lpage>172</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF00170853</pub-id><pub-id pub-id-type="pmid">2793368</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref072"><label>72</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tamaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Naomoto</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kimura</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kawashima</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shirakawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shigemitsu</surname><given-names>K</given-names></name>, <etal>et al</etal>. <source>Apoptosis in Normal Tissues Induced by Anti-Cancer Drugs</source>. <year>2003</year><month>Jan-Feb</month>;<volume>31</volume>(<issue>1</issue>):<fpage>6</fpage>&#8211;<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/147323000303100102</pub-id><pub-id pub-id-type="pmid">12635528</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref073"><label>73</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Shahbaz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <source>Integrin<italic toggle="yes">&#946;</italic>6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma</source>;<volume>21</volume>(<issue>5</issue>):<fpage>1183</fpage>&#8211;<lpage>1195</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1194</pub-id><pub-id pub-id-type="pmid">25549721</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref074"><label>74</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>. <source>An Active Molecule from Pulsatilla Chinensis, Pulsatilla Saponin A, Induces Apoptosis and Inhibits Tumor Growth of Human Colon Cancer Cells without or with 5-FU</source>;<volume>13</volume>(<issue>5</issue>):<fpage>3799</fpage>&#8211;<lpage>3802</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/ol.2017.5884</pub-id><pub-id pub-id-type="pmid">28529594</pub-id><pub-id pub-id-type="pmcid">PMC5431750</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref075"><label>75</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fujiya</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Konishi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Murakami</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kunogi</surname><given-names>T</given-names></name>, <etal>et al</etal>. <source>Bacteria-Derived Ferrichrome Inhibits Tumor Progression in Sporadic Colorectal Neoplasms and Colitis-Associated Cancer</source>;<volume>21</volume>(<issue>1</issue>):<fpage>21</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12935-020-01723-9</pub-id><pub-id pub-id-type="pmid">33407519</pub-id><pub-id pub-id-type="pmcid">PMC7789586</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref076"><label>76</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>ZN</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>S</given-names></name>. <source>Interleukin-1 Receptor Antagonist Enhances Chemosensitivity to Fluorouracil in Treatment of Kras Mutant Colon Cancer</source>;<volume>12</volume>(<issue>8</issue>):<fpage>877</fpage>&#8211;<lpage>892</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4251/wjgo.v12.i8.877</pub-id><pub-id pub-id-type="pmid">32879665</pub-id><pub-id pub-id-type="pmcid">PMC7443842</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref077"><label>77</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <source>Melatonin Synergizes the Chemotherapeutic Effect of 5-Fluorouracil in Colon Cancer by Suppressing PI3K/AKT and NF-<italic toggle="yes">&#954;</italic>B/iNOS Signaling Pathways</source>;<volume>62</volume>(<issue>2</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/jpi.12380</pub-id><pub-id pub-id-type="pmid">27865009</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref078"><label>78</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SW</given-names></name>. <source>Enhancement of Chemosensitivity in 5-Fluorouracil-Resistant Colon Cancer Cells with Carcinoembryonic Antigen-Specific RNA Aptamer</source>;<volume>46</volume>(<issue>4</issue>):<fpage>3835</fpage>&#8211;<lpage>3842</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11033-019-04826-3</pub-id><pub-id pub-id-type="pmid">31028570</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref079"><label>79</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Canman</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Lawrence</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Shewach</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Maybaum</surname><given-names>J</given-names></name>. <source>Resistance to Fluorodeoxyuridine-Induced DNA Damage and Cytotoxicity Correlates with an Elevation of Deoxyuridine Triphosphatase Activity and Failure to Accumulate Deoxyuridine Triphosphate</source>;<volume>53</volume>(<issue>21</issue>):<fpage>5219</fpage>&#8211;<lpage>5224</lpage>. <pub-id pub-id-type="pmid">8221659</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref080"><label>80</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>WS</given-names></name>. <source>5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies</source>;<volume>13</volume>(<issue>8</issue>):<fpage>1551</fpage>&#8211;<lpage>1569</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/molecules13081551</pub-id><pub-id pub-id-type="pmid">18794772</pub-id><pub-id pub-id-type="pmcid">PMC6244944</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref081"><label>81</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nord</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>DS</given-names></name>. <source>Loss of Murine Tumor Thymidine Kinase Activity in Vivo Following 5-Fluorouracil (FUra) Treatment by Incorporation of FUra into RNA</source>;<volume>42</volume>(<issue>12</issue>):<fpage>2369</fpage>&#8211;<lpage>2375</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0006-2952(91)90243-x</pub-id><pub-id pub-id-type="pmid">1722409</pub-id></mixed-citation></ref><ref id="pcbi.1010685.ref082"><label>82</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huehls</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Huntoon</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Joshi</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Baehr</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <etal>et al</etal>. <source>Genomically Incorporated 5-Fluorouracil That Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous Recombination</source>;<volume>89</volume>(<issue>1</issue>):<fpage>53</fpage>&#8211;<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1124/mol.115.100164</pub-id><pub-id pub-id-type="pmid">26494862</pub-id><pub-id pub-id-type="pmcid">PMC4702102</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>